Imidazopyridine compounds, preparation thereof and therapeutic use thereof

Abstract

The present invention provides compounds capable of inhibiting ERK5. Also provided are pharmaceutical compositions and pharmaceutical uses thereof, including in the treatment or prevention of conditions such as cancer.

Description

Technical Field

[0001] The present invention provides compounds that can inhibit ERK5. Also provided are pharmaceutical compositions and medical uses thereof, including use in treating or preventing conditions such as cancer. Background Art

[0002] The mitogen-activated protein kinase (MAPK) cascade is a highly conserved cellular pathway that transmits signals from the cell surface to the nucleus. This pathway plays an important role in cell proliferation, differentiation and migration, and it is well known that it is involved in the formation of cancer. The protein in this pathway includes extracellular signal-regulated kinase (ERK) protein; wherein ERK5 (expressed by MAPK7 gene) plays an important role in cell proliferation and epithelial development and neural differentiation (see, for example, Nishimoto et al., EMBO Reports (2006) 7 (8): 782-786). ERK5 is unique in ERK protein, with a large C-terminal domain containing a transcription initiation domain (TAD) and a nuclear localization signal and two proline-rich regions (see, for example, Guo et al., Exp Ther Med. (2020) 19: 1997-2007). Autophosphorylation of TADs is essential for transcription initiation (see, eg, Morimoto et al., J Biol Chem. (2007) 282(49):35449-35456).

[0003] ERK5 plays an important role in controlling cell proliferation and cell cycle progression, for example, via direct or indirect phosphorylation of, in particular, MEF2C, cMYC, SGK1, RSK, FOS, and FRA1 (see, for example, Paudel et al., Int J Mol Sci. (2021) 22: 7594-7614; Terasawa et al., Genes to Cells (2003) 8 (3): 263-273). ERK5 is involved in a variety of biological pathways, meaning that its activity is associated with many aspects of cancer progression, including tumor angiogenesis, metastasis, inflammation, sustained proliferation, and growth inhibition escape. Therefore, it provides an attractive target for regulating disease pathology and treating a variety of conditions. In previous studies, ERK5 inhibition or downregulation has been shown to block tumorigenesis in murine leukemia cells, reduce the growth of chronic myeloid leukemia cells, inhibit the growth of breast cancer cells and multiple myeloma cells, inhibit colon cancer cell proliferation, and have certain effects on the growth or survival of renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma, and hepatocellular carcinoma cells, among others (see, e.g., Stecca et al., Int J Mol Sci. (2019) 20: 1426-1446).

[0004] Therefore, ERK5 inhibition represents a promising approach to combat a variety of cancers. Several ERK5 inhibitors have been developed, and some of them are under clinical review. For example, WO 2019 / 170543 (Bayer AG and Bayer Pharma AG) discloses compounds that are said to be active as ERK5 inhibitors in the μM to nM concentration range. In particular, it has been reported that ERK5 inhibition is combined with BRAF-MEK1 / 2-ERK1 / 2 pathway inhibitors to overcome inherent resistance and hinder or delay some modes of acquiring resistance in the treatment of melanoma has potential uses (see, for example, Cook et al., Front. Cell Dev. Biol. (2022)).

[0005] Despite recent advances in cancer treatment with the development of targeted therapies and immunotherapies, not all cancer patients have access to effective treatment options. Therefore, there is a need to identify and develop new drugs. The present disclosure seeks to address this need by providing novel compounds that are useful as ERK5 inhibitors and for treating ERK5-related diseases and conditions. Summary of the invention

[0006] Therefore, a first aspect provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO 2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -C(O)NHR', -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CN groups, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 ) cycloalkyl or 3 to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H, methyl and phenyl, and Wherein each R" is independently selected from -OH, methyl, optionally substituted with -OCF 3 Substituted phenyl and tetrahydrofuranyl; L 1 Selected from direct bond, -O-, -CH 2 - and -CH =; R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halo, -OH, oxo, -NH 2 、-NHMe、-NO 2 、-CN、-SF 5 、-SiMe 3 、-B(OH) 2 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -SO 2 CH 3 , -NHC(O)Me, phenyl, benzyl, 1-λ 6 -2-thiazolidine-1,1-dione and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 The group substitution, And further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 optionally substituted at one ring atom with spirocyclic oxindolyl; L 2 Select from direct bonds, -CH 2 -、-CH 2 CH 2 -and-CH 2 O-, where L 2 (when present) optionally replaced by -NH 2 or methyl substitution; R 3 is selected from -H, halo, -OH, and methyl optionally substituted with -OH; R 4 Is -H or -NH 2 ; R 5 is -H or methyl; X is CH or N; Y is selected from CH, CF and N (provided that when Y is N, X is also N); E is selected from -C(O)-, -S(O) 2 - and -O- (provided that when E is -O-, X and Y are both CH); and n is 0, 1 or 2.

[0007] In an embodiment, the compound is a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , L 1 , X, Y and n are as defined above.

[0008] In an embodiment, the compound is a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , L 1 and n are as defined above.

[0009] In an embodiment, the compound is as defined above, wherein: R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO 2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -C(O)NHR', -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CN groups, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 ) cycloalkyl or 3 to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H, methyl and phenyl, and wherein each R" is independently selected from methyl, optionally substituted with -OCF 3 Substituted phenyl and tetrahydrofuranyl; R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more RB replace, Each R B Selected from halogen, -OH, -NH 2 、-NO 2 、-CN、-SF 5 、-B(OH) 2 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -SO 2 CH 3 , phenyl, benzyl, 1-λ 6 -2-thiazolidine-1,1-dione and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 ) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 The group substitution, And further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 is optionally substituted at one ring atom with spirocyclic oxindolyl; and X and Y are each independently selected from CH and N (provided that when Y is N, X is also N).

[0010] In an embodiment, the compound is a compound of formula (IC) or formula (ID) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and L 1 is as defined above.

[0011] In an embodiment, R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 6-membered heterocycloalkyl, 9- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl, 5- to 6-membered heteroaryl, and 9- to 10-membered heteroaryl, wherein R 2Optionally one or more R as defined above B replace.

[0012] In an embodiment, R 2 Selected from: Where R 2 Optionally one or more R as defined above B replace.

[0013] In an embodiment, R 2 Selected from: Where R 2 Optionally one or more R B Substitute, where each R B independently selected from halo, -NH 2 、-O(C 1 -C 3 )alkyl, -(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -SF 5 AND-NO 2 , and where -O(C 1 -C 3 )alkyl, -(C 1 -C 3 )alkyl and -(C 3 -C 6 ) Each of the cycloalkyl groups is optionally substituted by one or more independently selected from halo and -CF 3 The group is substituted.

[0014] In an embodiment, at least one R B Yes-SF 5 .

[0015] In an embodiment, R 2 yes:

[0016] In an embodiment, R 1 Selected from -H, -(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -(C 5 -C 7 )cycloalkenyl, -(C 6 -C 10) aryl, 4- to 9-membered heterocycloalkyl, 6-membered heterocycloalkenyl, 5- to 6-membered heteroaryl, and 9- to 10-membered heteroaryl, wherein R 1 Optionally one or more R as defined above A replace.

[0017] In an embodiment, R 1 Selected from: Where R 1 Optionally one or more R as defined above A replace.

[0018] In an embodiment, R 1 Selected from: Where R 1 Optionally one or more R A Substitute, where each R A Independently selected from -halo, -OH, -NH 2 , oxo, -(C 1 -C 3 )alkyl, -C(O)R" and -O(C 1 -C 3 )alkyl, wherein each (C 1 -C 3 )alkyl may be optionally substituted with one or more halo groups, and wherein each R" is independently selected from methyl, optionally substituted with -OCF 3 Substituted phenyl and tetrahydrofuranyl.

[0019] In an embodiment, R 1 Selected from -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 )aryl, 7 to 10-membered polycyclic (e.g., bicyclic) heterocycloalkyl, 5 to 8-membered heterocycloalkenyl, and 7 to 10-membered polycyclic (e.g., bicyclic) heteroaryl, wherein R 1 Optionally one or more R as defined above A Replace, or R 1 is one or more selected from -OH, -NH 2 and -O(C 1 -C 3 ) alkyl substituted-(C 1 -C 6 )alkyl.

[0020] In an embodiment, L 1Is a direct bond or -CH 2 -.

[0021] Another aspect provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 , L 1 , R 3 , R 4 and R 5 is as defined above, and wherein: R 2 Selected from -(C 3 -C 6 )cycloalkyl (e.g., cyclopropyl), -(C 6 -C 10 ) aryl, 5- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B independently selected from halo, -OH, oxo, -NO 2 , -NH 2 , -NHMe, -CN, -SF 5 , -SO 2 CH 3 ,-NHC(O)Me,-SiMe 3 , optionally substituted by one or more halogen groups -(C 1 -C 3 )alkyl, optionally substituted by one or more halo groups -O(C 1 -C 3 )alkyl, optionally substituted with -CF 3 Replaced-(C 3 -C 6 ) cycloalkyl, optionally substituted by one or more halo, -OH or -CF 3 substituted phenyl, benzyl optionally substituted by halogen, and 1-λ 6 -2-thiazolidine-1,1-dione, And further wherein, when R 2 When it is cyclopropyl, R 2 is optionally substituted at one ring atom with spirocyclic oxindolyl; and E is -C(O)- or -S(O) 2 -.

[0022] In another aspect, there is provided a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein: R1 Yes-H, -(C 1 -C 3 )alkyl, -(C 4 -C 6 )cycloalkyl, -(C 5 -C 7 )cycloalkenyl, -(C 6 -C 10 ) aryl or 4 to 9 membered heterocycloalkyl, 6 membered heterocycloalkenyl, 5 to 6 membered heteroaryl and 9 to 10 membered heteroaryl, wherein R 1 Optionally one or more R A Substitute, where each R A are independently selected from halo, -OH, oxo, -NH 2 , -NHMe, -C(O)OH, -C(O)Me, -SO 2 CH 3 、-NHC(O)R”、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, cyclopropyl, oxetanyl, sulfolane, phenyl, benzyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH and -NH 2 The group substitution, wherein each R" is independently selected from methyl and tetrahydrofuranyl; L 1 Is a direct bond or -CH 2 -;and R 2 Selected from -(C 3 -C 6 )cycloalkyl, -(C 6 -C 10 ) aryl, 5- to 6-membered heterocycloalkyl, and 5- to 10-membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -NO 2 、-NH 2 、-NHMe、-NHAc、-O(C 1 -C 3 ) alkyl, -SF 5 、-SiMe 3 、-(C 1 -C 3 ) alkyl, 1-λ6 -2-thiazolidine-1,1-dione, phenyl, benzyl and -optionally -CF 3 Replaced (C 3 -C 6 )cycloalkyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl, phenyl and benzyl are each optionally substituted by one or more independently selected from halo, -NH 2 and -CF 3 and further wherein, when R 2 When it is cyclopropyl, R 2 Optionally substituted at one ring atom with spirocyclic oxindolyl.

[0023] Another aspect provides a compound of formula (IV) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined above, and wherein: p is 1, 2, 3, 4, or 5; and Each R B are independently selected from halo, -NO 2 、-NH 2 、-NHMe、-NHAc、-OCH 3 、-OCF 3 、-SF 5 、SiMe 3 , (C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl, 1-λ 6 -2-thiazolidine-1,1-dione, phenyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -NH 2 and -CF 3 The group is substituted.

[0024] Another aspect provides a compound of formula (V) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined above, and wherein: R B1 is -H, or is selected from halo (e.g., -F or -Cl), -OH, -NH 2 , -NHMe, -NHAc and -NO 2 ;and R B2 Selected from halide (e.g. -Br), -SF 5 、-SO 2 CH 3 、-SiMe 3 , optionally substituted by one or more halogen groups -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, 1-trifluoromethylcycloprop-1-yl, and optionally substituted by one or more independently selected from halo or -NH 2 A phenyl group substituted with a group.

[0025] In an embodiment, R B2 Yes-SF 5 .

[0026] In another aspect, there is provided a compound of formula (VIII), (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 5 and n are as defined above.

[0027] Another aspect provides a compound selected from the group consisting of: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, - trans-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-aminocyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -1-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]azetidin-1-yl]ethanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -5-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one, -[4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(azetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(4-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-[1-(2,2-difluoroethyl)azetidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(4-chloro-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-nitro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(4-methoxy-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -6-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-3-(trifluoromethyl)-1H-pyridin-2-one, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)phenyl]methanone, -[4-(trifluoromethoxy)phenyl]-[4-[2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, --[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, --[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(3-methoxy-1-bicyclo[1.1.1]pentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]methanone, -[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-pyrrolidin-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-[(1-methyl-4-piperidinyl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and -[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and pharmaceutically acceptable salts thereof.

[0028] Another aspect provides a compound selected from the group consisting of: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-naphthyl-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -1H-indazol-3-yl-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]methanone; -(1-methyl-5-phenyl-pyrazol-3-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3-amino-2-naphthyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-3,4,5,6-tetrafluoro-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[1-isopropyl-2-(trifluoromethyl)benzimidazol-5-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-4-methylsulfonyl-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-(3-hydroxyphenyl)cyclopropyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[2-chloro-4-(trifluoromethyl)phenoxy]-1-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]propan-1-one; -(3-phenylcyclopentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-hydroxy-1-[2-(trifluoromethyl)phenyl]pyrazol-3-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[3-amino-4-phenyl-5-(trifluoromethyl)-2-thienyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(7-hydroxy-1H-indol-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -1-[4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1-piperidinyl]ethanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)cyclohexyl]methanone; -1-[4-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1-piperidinyl]ethanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]benzothiophene-5-carbonitrile; -(5-amino-1-phenyl-pyrazol-4-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[2-oxo-2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]ethyl]-4H-1,4-benzoxazin-3-one; -1-(3,4-difluorophenyl)-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -[4-(3-chloro-4-fluoro-phenyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(7-amino-2-methyl-pyrazolo[1,5-a]pyrimidin-6-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -1-[(2-chlorophenyl)methyl]-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -1-(4-fluorophenyl)-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -[1-[(2-chlorophenyl)methyl]pyrazol-4-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-aminophenyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3,6-dichloroimidazo[1,2-a]pyridin-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(4-amino-1-ethyl-pyrazol-3-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3-aminoquinoxalin-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]spiro[cyclopropane-1,3'-indolin]-2'-one; -[1-(2-chlorophenyl)pyrrolidin-3-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-4,5-dichloro-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[1-(4-fluorophenyl)imidazol-4-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3-amino-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)cyclohexyl]methanone; -[3-Fluoro-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(4-methylpiperazin-1-yl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[2-(5-chloro-2-hydroxy-phenyl)thiazol-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-fluoro-5-hydroxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]phenyl]tetrahydrofuran-2-carboxamide; -[4-[2-[5-(hydroxymethyl)isoxazol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -1-ethyl-3-hydroxy-6-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]quinoxalin-2-one; -[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -(4-bromophenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,4-dioxan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -4-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclohexanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-(4-trimethylsilylphenyl)methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2,2-difluoro-1,3-benzodioxol-5-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(4-bromo-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-(trifluoromethyl)-1H-indol-6-yl]methanone; -[4-(Cyclopropyloxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -2-tetrahydropyran-4-yl-7-[1-[4-(trifluoromethoxy)phenyl]sulfonyl-4-piperidinyl]-3H-imidazo[4,5-b]pyridine; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[rac-(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[1-(oxetan-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(oxetan-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-3-fluoro-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[rac-(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)cyclohexyl]-[4-(trifluoromethoxy)-1-piperidinyl]methanone; -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)cyclohexyl]-[4-(trifluoromethoxy)-1-piperidinyl]methanone; -[4-[2-(4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclopent-3-en-1-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2-amino-4-bromo-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-5-(trifluoromethoxy)phenyl]acetamide; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,6-tetrahydropyridin-5-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-phenylpyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-fluoropyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-amino-3,3,3-trifluoro-propyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[6-(aminomethyl)-3-pyridinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[rac-(3R,4S)-4-(4-pyridinyl)pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-2-bicyclo[2.2.1]hept-5-enyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-2-thienyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidine-4-carbonitrile; -[4-[2-[2-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-aminotetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,4-tetrahydroisoquinolin-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-5-hydroxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1H-indol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(azetidin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone 2,2,2-trifluoroacetate -[4-[2-(3-oxa-9-azabicyclo[3.3.1]non-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-amino-3-pyridinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[piperazin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-aminocyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[3-(methylamino)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-azabicyclo[4.1.0]hept-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-hydroxy-6-(trifluoromethyl)-3-quinolyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-oxabicyclo[3.1.0]hexan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[4-hydroxy-2-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]phenyl]acetamide; -5,6-dimethyl-3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyridin-2-one; -1-[3,5-dimethyl-4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyrrol-2-yl]ethanone; -[4-[2-[1-(1,1-dioxothiol-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1-methylsulfonylazetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-hydroxy-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1,4-oxazepan-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(1,1,2,2-tetrafluoroethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[rac-(1S,3S)-3-aminocyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclopent-3-en-1-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(azepan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-hydroxyphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[rac-(1R,3S)-3-aminocyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-(3-fluoro-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,6-tetrahydropyridin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]bicyclo[1.1.1]pentane-1-carboxylic acid; -3-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-6-(trifluoromethyl)-1H-pyridin-2-one; -[4-(difluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,1-dioxothiol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(trans)-4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclohexanecarboxylic acid; -(cis)-[4-[2-[3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,1-dioxothiol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-hydroxy-4-methyl-cyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-hydroxy-4-methyl-cyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,2,3,6-tetrahydropyridin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[Azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfuryl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone hydrochloride; -[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-(methylamino)-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -3-methyl-3-[7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclobutanone; -[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[(cis)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ6 -sulfanyl)phenyl]methanone; -[(trans)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-fluoro-4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[(cis)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(trans)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]octan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]octan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-fluoro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[4-(hydroxymethyl)-1-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-thiomorpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -5-[6-fluoro-7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one; -(trans)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-cyclopentyl-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-[6-fluoro-2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclopentyl-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-5-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-(4-(6-fluoro-2-(4-hydroxy-4-methylcyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperidin-1-yl)(4-(pentafluoro-λ 6 -sulfuryl)phenyl)methanone; -(cis)-[4-[6-fluoro-2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-[6-fluoro-2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -4-(6-fluoro-2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3,4,4a,5,7,7a-hexahydro-2H-furo[3,4-b][1,4]oxazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-[6-fluoro-7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2,3,4a,5,7,7a-hexahydrofuro[3,4-b][1,4]oxazine-4-carboxylic acid; -[4-[2-(1,1-dioxo-1,4-thiazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; and -7-[6-fluoro-7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2-oxa-5-azaspiro[3.5]nonane-5-carboxylic acid, and pharmaceutically acceptable salts thereof.

[0029] Another aspect provides a compound as defined above, wherein the compound has an IC against ERK5 of less than about 2 μM (e.g., less than about 1 μM, 0.5 μM, 0.2 μM, 100 nM or 50 nM). 50 value.

[0030] Another aspect provides a pharmaceutical composition comprising a compound as defined above and at least one pharmaceutically acceptable excipient or carrier.

[0031] Another aspect provides a compound or pharmaceutical composition as defined above for use in therapy.

[0032] Another aspect provides a compound or pharmaceutical composition as defined above for use in the treatment or prevention of cancer.

[0033] In embodiments, the cancer is characterized by increased expression of MAPK7 and / or increased activity of ERK5.

[0034] In embodiments, the cancer is selected from leukemia, breast cancer, multiple myeloma, colon cancer, renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma, and hepatocellular carcinoma. DETAILED DESCRIPTION

[0035] Although specific embodiments of the present disclosure will now be described with reference to the specification and examples, it should be understood that such embodiments are presented by way of example only and illustrate only a small portion of the many possible specific embodiments that can represent the application of the principles of the present disclosure. Given the benefit of this disclosure, many variations and modifications will be apparent to those skilled in the art, and as further defined in the appended claims, the various variations and modifications are considered to be within the spirit and scope of the present disclosure.

[0036] definition

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present disclosure, exemplary methods, devices and materials are now described. All techniques and patent publications cited herein are incorporated herein by reference in their entirety.

[0038] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of chemical synthesis, tissue culture, immunology, molecular biology, microbiology, cell biology, recombinant DNA, and the like, which are within the skill of the art. See, e.g., Michael R. Green and Joseph Sambrook, Molecular Cloning (4th ed., Cold Spring Harbor Laboratory Press 2012); the series Ausubel et al., eds. (2007) Current Protocols in Molecular Biology; the series Methods in Enzymology (Academic Press, Inc., NY); MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press at Oxford University Press); MacPherson et al. (1995) PCR 2: A Practical Approach; Harlow and Lane, eds. (1999) Antibodies, A Laboratory Manual; Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique, 5th ed.; Gait, ed. (1984) Oligonucleotide Synthesis; U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acids Hybridization; Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins (1984) Transcription and Translation; Immobilized Cells and Enzymes (IRL Press (1986)); Perbal (1984) APractical Guide to Molecular Cloning; Miller and Calos (1987) Gene TransferVectors for Mammalian Cells (Cold Spring Harbor) Laboratory); Makrides editor (2003) Gene Transfer and Expression in Mammalian Cells;Mayer and Walker (1987) Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Herzenberg et al. (1996) Weir's Handbook of Experimental Immunology; Manipulating the Mouse Embryo: ALaboratory Manual, 3rd Edition (Cold Spring Harbor Laboratory Press (2002)); Sohail (editor) (2004) Gene Silencing by RNA Interference: Technology and Application (CRC Press). ;

[0039] All numerical designations, such as pH, temperature, time, concentration, molecular weight, etc. (including ranges), are approximate values ​​that vary (+) or (-) in increments of, for example, 0.1 or 1.0, where appropriate. It is understood that, although not always expressly stated, all numerical designations are preceded by the term "about," which is used to indicate a conventional level of variability. For example, a numerical designation of a value that is "about" a given value may vary by ±10% of the value; alternatively, the variation may be ±5%, ±2%, or ±1% of the value. Although not always expressly stated, it is also understood that the agents described herein are merely exemplary and that equivalents of such agents are known in the art.

[0040] Unless the context clearly indicates otherwise, as used in the specification and claims, the singular forms "a / an" and "the" include plural referents. For example, the term "a cell" includes a plurality of cells, including mixtures thereof. Unless the context clearly states or is clear, as used herein, the term "or" should be understood to be inclusive. The term "including" is used herein to mean and is used interchangeably with the phrase "including but not limited to".

[0041] As used herein, the term "comprising" or "comprises" is intended to mean that compositions and methods include the elements listed, but do not exclude other elements. When used to define compositions and methods, "essentially consisting of..." should mean excluding other elements of any importance for the purpose. Therefore, a composition consisting essentially of the elements defined herein will not exclude trace contaminants and pharmaceutically acceptable carriers from separation and purification methods, such as phosphate buffered saline, preservatives, etc. "Consisting of..." should mean excluding other ingredients more than trace elements and substantial method steps for applying the compositions of the present disclosure, or process steps for producing the compositions or achieving the desired results. The embodiments defined by each of these transitional terms are within the scope of the present disclosure. The use of the term "comprising" herein is intended to cover and disclose corresponding statements in which the term "comprising" is replaced by "essentially consisting of..." or "consisting of..."

[0042] "Subject," "individual," or "patient" are used interchangeably herein and refer to a vertebrate, such as a mammal. Mammals include, but are not limited to, rodents, livestock, sports animals, pets, and primates; for example, mice, rats, rabbits, monkeys, cattle, sheep, pigs, dogs, cats, horses, and humans. In a specific embodiment, the mammal is a human.

[0043] "Administering" is defined herein as a means of providing a medicament or a composition comprising a medicament to a subject in a manner that causes the medicament to contact the subject's body (e.g., in the body thereof). Such administration may be by any route, including but not limited to oral, transdermal (e.g., through the vagina, rectum, or oral mucosa), by injection (e.g., subcutaneous, intravenous, parenteral, intraperitoneal, or into the central nervous system), or by inhalation (e.g., oral or nasal). Administration may also involve providing a substance or composition to a portion of the subject's body surface, such as by topical application to the skin. Pharmaceutical preparations are of course administered in a form suitable for each route of administration.

[0044] "Treating" or "treatment" of a disease includes: (1) preventing the disease, i.e., preventing the clinical symptoms of the disease from appearing in a patient who may be susceptible to the disease but does not yet experience or exhibit symptoms of the disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; and / or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

[0045] The term "suffering from" as it relates to the term "treating" refers to a patient or individual who has been diagnosed with or is susceptible to a disease. A patient may also be said to be "at risk for" a disease due to a history of the disease in their family pedigree or due to the presence of a genetic mutation associated with the disease. A patient at risk for a disease has not yet developed all or part of the characteristic pathology of the disease.

[0046] An "effective amount" or "therapeutically effective amount" is an amount sufficient to achieve a beneficial or desired result. An effective amount can be administered in one or more administrations, applications or doses. Such delivery depends on many variables, including the time period over which a single dosage unit is used, the bioavailability of the therapeutic agent, the route of administration, etc. However, it should be understood that for any particular subject, the specific dosage level of the therapeutic agent of the present disclosure depends on a variety of factors, including, for example, the activity of the specific compound employed, the age, weight, general health, sex and diet of the subject, the time of administration, the rate of excretion, the drug combination, the severity of the specific disorder being treated, and the form of administration. Generally, the therapeutic dose can be adjusted stepwise to optimize safety and efficacy. Typically, dose-effect relationships from in vitro and / or in vivo testing can initially provide useful guidance in administering appropriate doses to patients. Generally, one would wish to administer a compound in an amount effective to achieve serum levels comparable to the concentrations found to be effective in vitro. The determination of these parameters is well within the skill of the art. These considerations, as well as effective formulations and administration procedures, are well known in the art and are described in standard textbooks. Consistent with this definition, as used herein, the term "therapeutically effective amount" is an amount sufficient to treat (e.g., improve) one or more symptoms associated with a disorder. The total daily dose may be administered in single or divided doses and may be outside the typical range given herein at the discretion of the physician.

[0047] As used herein, the terms "increased" and "elevated" are used interchangeably and encompass any measurable increase in biological function and / or biological activity and / or concentration. For example, the increase can be at least about 10%, such as at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, such as at least about 95%, 96%, 97%, 98%, 99% or 100%. Therefore, relative to a control or baseline amount or function or activity or concentration, the increase can be at least about 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times, such as at least about 20 times, 25 times, 50 times, 100 times or higher.

[0048] As used herein, in a sample or cancer or patient, the term "increased expression" and / or "increased activity" of a substance (such as ERK5) generally refers to an increase in the amount of a substance (e.g., a MAPK7 gene product or an ERK5 protein), although it can also represent an increase in the biological activity of the substance (e.g., constitutive activation of phosphorylation and / or reduced phosphorylation site recognition of ERK5). For example, the increase can be about 5%, such as about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%, such as about 96%, 97%, 98%, 99% or 100%. Thus, relative to the amount (or activity) of a substance (e.g., ERK5) in one or more control samples (e.g., individuals or groups of individuals with a disease or disorder (e.g., cancer) or an internal control as determined by techniques known in the art), the increase can be about 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold, such as about 20-fold, 25-fold, 50-fold, 100-fold, or more. "Increased expression" or "increased activity" of ERK5 in a subject can also be determined if the expression and / or activity of ERK5 is increased by one standard deviation, two standard deviations, three standard deviations, four standard deviations, five standard deviations, or more relative to the average amount (mean) or median amount of ERK5 in a control sample group or a baseline sample group or a retrospective analysis of patient samples. Such control or baseline expression levels can be predetermined or measured prior to measurement in a sample or cancer or subject, or can be obtained from a database of such control samples, as practiced in the art.

[0049] As used herein, the term "pharmaceutically acceptable excipient" encompasses any standard pharmaceutical excipient, such as described in Remington's Pharmaceutical Sciences (20th edition, Mack Publishing Co. 2000). Such excipients include carriers (such as phosphate buffered saline solutions), water and emulsions (such as oil-in-water or water-in-oil emulsions) and various types of wetting agents. Pharmaceutical compositions may also include stabilizers, preservatives, adjuvants, fillers, binders, lubricants, etc.

[0050] As used herein, the term "alkyl" means a saturated linear or branched group consisting essentially of carbon atoms and a corresponding number of hydrogen atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and the like. Other alkyl groups will be apparent to those skilled in the art given the benefit of this disclosure. The term "(C 1 -C 3 )alkyl", "(C 1 -C 6)alkyl" etc. have equivalent meanings, i.e., saturated linear or branched groups consisting essentially of 1 to 3 (or 1 to 6) carbon atoms and a corresponding number of hydrogen atoms. The definition of "alkyl" is not limited to other groups containing alkyl (such as "O(C 1 -C 3 The term "haloalkyl" means an alkyl group substituted with one or more halogens. Exemplary haloalkyl groups include trifluoromethyl, trifluoroethyl, difluoroethyl, pentafluoroethyl, chloromethyl, and the like. One or more carbon atoms in the alkyl backbone may be substituted (or bonded) with a heteroatom via multiple bonds (e.g., double bonds); for example, a carbon atom of an alkyl group may be bonded to oxygen via a double bond (i.e., substituted with oxo to provide a carbonyl functionality). The presence of such a substituent does not prevent the carbon backbone of the group from being considered an alkyl group.

[0051] As used herein, the term "cyclic group" means a saturated, partially or completely unsaturated, or aromatic group having at least 3 to 10 atoms (i.e., ring atoms) forming a ring. In the case where a cyclic group is defined as having a certain number of members, the terms "member", "membered", etc. are used to represent the number of ring atoms in the cyclic group. For example, a 5-membered cyclic group (e.g., a 5-membered heterocyclic group) contains 5 ring atoms. It should be understood that a cyclic group can be part of a larger ring system; for example, bicyclo [4.3.0] nonane includes two carbocyclic groups (i.e., a cyclohexane group and a cyclopentane group), which are fused to form a carbocyclic system constituting a molecule. The term "cyclic group" is intended to encompass carbocyclic groups and heterocyclic groups. The term "carbocycle" refers to a group having at least 3 to 9 carbon atoms forming a ring. The term "heterocycle" refers to a group having at least 3 to 10 ring-forming atoms, wherein at least 1 to 9 of the ring atoms are carbon and the remaining at least 1 to 9 ring atoms (ie, heteroatoms) are independently selected from nitrogen, sulfur and oxygen.

[0052] As used herein, the term "spiro" or "spirocyclic" in reference to a cyclic group means that a first cyclic group within a polycyclic ring system is attached to a second cyclic group within the polycyclic ring system, wherein the ring atoms of the first cyclic group and the ring atoms of the second cyclic group have only one common atom, i.e., the first and second cyclic groups share only one common ring atom. For example, spiro[5.5]undecyl comprises two cyclohexane rings having a single common carbon ring atom.

[0053] As used herein, the term "fused" in reference to cyclic groups means that a first cyclic group within a polycyclic ring system is attached to a second cyclic group within the polycyclic ring system, wherein the ring atoms of the first cyclic group and the ring atoms of the second cyclic group have two adjacent common atoms, i.e., the first and second cyclic groups share two common ring atoms. For example, bicyclo[4.4.0]decyl comprises two cyclohexane rings having two adjacent common carbon ring atoms.

[0054] As used herein, the term "bridged" in reference to cyclic groups means that a first cyclic group within a polycyclic ring system is attached to a second cyclic group within the polycyclic ring system, wherein the ring atoms of the first cyclic group and the ring atoms of the second cyclic group have more than two adjacent common atoms, i.e., the first and second cyclic groups share three or more common ring atoms. For example, bicyclo[3.3.1]nonyl comprises two cyclohexane rings having three adjacent common carbon ring atoms.

[0055] Within the structural formulae described herein, any ring system (including any spiro, fused or bridged ring system) can be connected to the rest of the molecule by any atom with suitable valence. For example, a bicyclic ring can be connected to another part of the molecule by a ring atom (e.g., a secondary carbon atom or a heteroatom (such as N)) or a bridgehead atom (e.g., a tertiary carbon atom). Spirocyclic rings, fused rings, and bridged rings can be fully unsaturated, partially unsaturated, or fully saturated, and can have aromatic characteristics in one or more of their constituent rings.

[0056] As used herein, the term "cycloalkyl" means a saturated group having at least 3 to 9 carbon atoms (i.e., ring atoms) forming a ring. Exemplary cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. It should be understood that a cycloalkyl can be monocyclic or polycyclic (e.g., fused, bridged, or spirocyclic). In the case of a polycyclic cycloalkyl, there are other rings, such as 1 or other rings, all of which contain 3 to 7 carbon atoms (i.e., ring atoms). Exemplary cycloalkyls with such other rings include bicyclo[1.1.1]pentyl. The term "(C 3 -C 7 )cycloalkyl" means a cycloalkyl group containing 3 to 7 carbon atoms in the ring portion of the group which may be monocyclic or polycyclic (e.g., fused, bridged or spirocyclic), such as cyclopropyl (having 3 ring carbon atoms) or bicyclo[1.1.1]pentyl (having 5 ring carbon atoms). One or more ring atoms of the cycloalkyl group may be substituted (i.e., bonded) by a heteroatom through a double bond (e.g., a cycloalkyl group is substituted by oxo). The presence of such a substituent does not prevent the carbon backbone of the group from being considered a cycloalkyl group.

[0057] As used herein, the term "cycloalkenyl" means an unsaturated (i.e., partially or completely unsaturated) group having at least 3 to 9 carbon atoms (i.e., ring atoms) forming a ring. The term "cycloalkenyl" is not intended to encompass cyclic groups having aromatic characteristics (these groups are considered to be aryl groups as defined herein). Exemplary cycloalkenyl groups include cyclohexenyl. It should be understood that cycloalkenyl groups can be monocyclic or polycyclic (e.g., bridged). In the case of polycyclic cycloalkenyls, there are other rings, such as 1 or more other rings, all of which contain 3 to 9 carbon atoms (i.e., ring atoms). Those other rings can be saturated or unsaturated. Exemplary cycloalkenyls with such other rings include bicyclo[2.2.1]hept-5-enyl. The term "(C 4 -C 8 The term "cycloalkenyl" refers to a cycloalkenyl group having 4 to 8 carbon atoms in the ring portion of the group, such as cyclohexenyl (having 6 ring carbon atoms) or bicyclo[2.2.1]hept-5-enyl (having 7 ring carbon atoms). The double bond (or double bonds) in a cycloalkenyl group are typically between ring carbon atoms (i.e., endocyclic), but may also be between a ring carbon atom and an adjacent non-ring carbon atom (i.e., exocyclic).

[0058] As used herein, the term "aryl" means an aromatic group having at least 6 carbon atoms (i.e., ring atoms) forming a ring. It should be understood that an aryl group can be monocyclic or polycyclic (e.g., fused). In the case of a polycyclic aryl group, there are other rings, such as 1 or more other rings, all of which contain at least 3 carbon atoms (i.e., ring atoms). The other rings may also contain one or more heteroatoms and they may be saturated, unsaturated or aromatic. Polycyclic aryl groups are typically attached to the rest of the molecule via the aromatic ring (and typically not via the ring containing heteroatoms). In an embodiment, the polycyclic aryl group does not contain any ring heteroatoms. Examples of aryl groups include phenyl and naphthyl, as well as indenyl and indanyl. Other aryl groups include, for example, tetrahydroisoquinolinyl, which is bonded to the rest of the molecule via its phenyl ring. The term "(C 6 -C 10 )aryl" means that the aryl group contains 6 to 10 carbon atoms in the ring portion of the group (which may be monocyclic or polycyclic (e.g., fused)), such as phenyl (having 6 ring carbon atoms) or indanyl (having 9 ring carbon atoms).

[0059] As used herein, the term "heterocycloalkyl" means a saturated group having at least 3 to 10 atoms (i.e., ring atoms) forming a ring, wherein at least 1 to 9 of the ring atoms are carbon, and the remaining at least 1 to 9 ring atoms (i.e., heteroatoms) are independently selected from nitrogen, sulfur and oxygen. For example, the term "4 to 10 yuan heterocycloalkyl" means a saturated group containing 4 to 10 ring atoms (one or more of which are heteroatoms). The heterocycloalkyl ring may have an oxo substituent (e.g., 2-oxopyrrolidinyl) that is usually adjacent to a heteroatom, but the oxygen atom does not form a part of the ring and is excluded from the number of ring atoms. The presence of such a substituent does not prevent a ring (or multiple rings) of the group from being considered as a heterocycloalkyl. Exemplary heterocycloalkyls include tetrahydrofuranyl, piperidinyl, morpholinyl and piperazinyl. Any ring sulfur atom may optionally carry one or more side chains (pendant) (i.e., non-ring) oxygen atoms, such as found in, for example, sulfolane. In the case of polycyclic heterocyclic groups, there are other rings, such as 1 or more other rings, which all contain 3 to 7 ring atoms selected from carbon, nitrogen, sulfur and oxygen. The other rings may be saturated, or partially or completely unsaturated (e.g., with aromatic features). Polycyclic heterocyclic groups include fused systems, bridged systems and spiro systems. In the case where polycyclic heterocycloalkyl contains an unsaturated fused ring, the group is usually not bonded to the rest of the molecule via the fused ring. Exemplary heterocyclic groups with such other rings include 2-oxaspiro [3.3] heptyl, tetrahydroisoquinolyl, 1-azaspiro [3.3] heptyl-2-ketone and 2-azabicyclo [4.1.0] heptyl. In the case where heterocycloalkyl is described as "X to Y yuan" (when X and Y are integers), this means that heterocycloalkyl contains the total number of ring atoms from X to Y. Thus, for example, a "4- to 7-membered heterocycloalkyl" contains a total of 4, 5, 6 or 7 ring atoms, such as tetrahydropyranyl (6 ring atoms).

[0060] As used herein, the term "heterocycloalkenyl" means an unsaturated (i.e., partially or completely unsaturated) group having at least 3 to 6 atoms (i.e., ring atoms) forming a ring, wherein at least 1 to 5 of the ring atoms are carbon, and the remaining at least 1 to 5 ring atoms (i.e., heterocyclic atoms) are independently selected from nitrogen, sulfur and oxygen. The heterocycloalkenyl ring may have an oxo substituent that is usually adjacent to a heteroatom, but the oxygen atom cannot form a part of the ring and is excluded from the number of ring atoms. Exemplary heterocycloalkenyls include tetrahydropyridyl. Any ring sulfur atom may optionally carry one or more dangling (i.e., non-ring) oxygen atoms. It should be understood that the heterocycloalkenyl may be monocyclic or polycyclic (e.g., bridged). In the case of polycyclic heterocycloalkenyls, there are other rings, such as 1 or more other rings, all of which contain 3 to 6 ring atoms selected from carbon, nitrogen, sulfur and oxygen. The other rings may be saturated, or partially or completely unsaturated (e.g., with aromatic features). Polycyclic heterocycloalkenyls include fused systems, bridged systems, and spirocyclic systems. In the case where the polycyclic heterocycloalkenyl contains an unsaturated fused ring, the group is generally not bonded to the rest of the molecule via the fused ring. Exemplary heterocycloalkenyls with such other rings include tetrahydroindole. In the case where heterocycloalkenyl is described as "X to Y yuan", this means that the heterocycloalkenyl contains the total number of ring atoms from X to Y. Therefore, for example, "5 to 8 yuan heterocycloalkenyl" contains a total of 5, 6, 7 or 8 ring atoms, such as dihydropyranyl (6 ring atoms).

[0061] As used herein, the term "heteroaryl" means an aromatic (i.e., aromatic) group generally containing 6 to 10 ring atoms, wherein 1 to 9 of the ring atoms are carbon, and the remaining 1 to 9 ring atoms (i.e., heterocyclic atoms) are independently selected from nitrogen, sulfur, and oxygen. It should be understood that heteroaryl can be monocyclic or polycyclic (e.g., fused). In the case of polycyclic heteroaryl, there are other rings, such as 1 or more other rings, all of which contain at least 3 atoms (i.e., ring atoms), and the other rings can be optionally aromatic. Examples of heteroaryl include monocyclic groups (such as pyridyl and 2-oxopyridyl) and polycyclic groups (such as indolyl). In the case where heteroaryl is described as "X to Y yuan", this means that the heteroaryl contains the total number of ring atoms from X to Y. Therefore, for example, "5 to 10 yuan heteroaryl" contains a total of 5, 6, 7, 8, 9 or 10 ring atoms, such as indolyl (9 ring atoms).

[0062] As used herein, the terms "halo" and "halogen" mean fluorine, chlorine, bromine or iodine. These terms are used interchangeably and may refer to a halogen group or a halogen atom itself. Given the context in which this term is used in this disclosure, one skilled in the art will be able to readily determine the identity of the term.

[0063] As used herein, the term "CN" means a group having a carbon atom connected to a nitrogen atom via a triple bond. The CN group is attached via its carbon atom.

[0064] As used herein, the term "oxo" means a group in which an oxygen atom is attached to the atom carrying the group via a double bond. For example, in the case of a carbon atom carrying an oxo group, it forms a carbon-oxygen double bond. It should be understood that not all atoms within a given structure can be substituted with oxo, which will depend on the free valence of the atom to be substituted.

[0065] As used herein, "-C(O)-" means “-S(O) 2 -" means "-C(O)NH-" means And "-NHC(O)-" means

[0666] Compounds of the present disclosure are described in particular by means of structural formulas. It should be understood that these formulas generally only show one form of the compound (e.g., resonance form, tautomeric form, etc.), and some compounds may exist in more than one such form. This will be clear to the skilled reader. The present disclosure includes all possible tautomers of the compounds characterized by the structural formulas above and below, including as a single tautomer or as any mixture of tautomers in any ratio. It should also be understood that some compounds of the present invention may exist in one or more isomers (e.g., stereoisomers). The present disclosure includes all possible stereoisomers, enantiomers, diastereomers, etc. of the compounds described above and below, as well as their cis-forms and trans-forms and conformers. The purification and separation of isomers can be accomplished by the methods described below and by techniques known in the art. For example, the optical isomers of a compound can be obtained by splitting the racemic mixture of its diastereoisomer salts (e.g., using an optically active acid or base, or by forming covalent diastereomers). Different methods for separating optical isomers involve the use of chiral chromatography (e.g., HPLC columns using chiral phases), with or without conventional derivatization. Enzymatic separations, with or without derivatization, may also be useful, and the optically active compounds of the disclosure may likewise be obtained by chiral synthesis using optically active starting materials. The disclosure includes all possible stereoisomers of the compounds described herein as single stereoisomers or as any mixture of said stereoisomers (e.g., (R)- or (S)-isomers) in any ratio.

[0067] The compounds of the present disclosure may exist in the form of free acids or free bases, or may exist as addition salts with suitable acids or bases. For example, basic compounds of formula (I) may be provided as pharmaceutically acceptable acid addition salts with acids such as HCl, TFA or formic acid (e.g., HCl). Methods for forming salts are described below and are also known in the art (see, e.g., Berge et al., J Pharm Sci. (1977) 66: 1-19).

[0068] As used herein, the term "pharmaceutically acceptable" when used in conjunction with a salt means a salt of a compound disclosed herein that can be administered without producing any one or more substantial undesirable biological effects, or without producing any one or more deleterious interactions with any other components that may be contained in the pharmaceutical composition.

[0069] The recitation of a list of chemical groups in any definition of a variable herein includes defining that variable as any single group or combination of the listed groups. The recitation of an embodiment of a variable or aspect herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.

[0070] The compositions and methods provided herein can be combined with one or more of any other compositions and methods provided herein.

[0071] The following abbreviations and empirical formulas are used in this article: Ac Acetyl ADDP 1,1'-(azodicarbonyl)dipiperidin ATP Adenosine triphosphate BOC / Boc tert-Butyloxycarbonyl Bn Benzyl BuLi Butyl lithium CDI 1,1'-Carbonyldiimidazole DAD diode array detection DBU 1,8-diazabicyclo[5.4.0]undec-7-ene DCM Dichloromethane DIEA / DIPEA Diisopropylethylamine Diox 1,4-Dioxane 4-DMAP 4-Dimethylaminopyridine DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide 4EBP1 Eukaryotic translation initiation factor 4E-binding protein 1 EDC / EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide ee enantiomeric excess ERK Extracellular signal-regulated kinase EtOAc / AcOEt Ethyl acetate ES Electrospray ionization FRET Förster Resonance Energy Transfer HATU Azabenzotriazole tetramethyluronium hexafluorophosphate IPA Isopropyl Alcohol Ir[dF(CF3)ppy]2(dtbpy))PF6 [4,4′-bis(1,1-dimethylethyl)-2,2′-bipyridyl-N1,N1′]bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridyl-N]phenyl-C]iridium(III) hexafluorophosphate LC / MS Liquid chromatography / mass spectrometry LED Light Emitting Diode MAPK / MEK Mitogen-activated protein kinase Me Methyl MeCN / ACN Acetonitrile MeOH Methanol MeTHF 2-Methyltetrahydrofuran MS mass spectrometry MTBE Methyl tert-butyl ether Pd / C Palladium Carbon PDA Photodiode Array Pd 2 (dba) 3 Tris(dibenzylideneacetone)dipalladium(0) Pd(dppf)Cl 2 [1,1′-Bis(diphenylphosphino)ferrocene]palladium(II) dichloride Pd(PPh 3 ) 2 Cl 2 Bis(triphenylphosphine)palladium(II) dichloride PhOK Potassium Phenolate PMB p-Methoxybenzyl PPh 3 Triphenylphosphine Py Pyridine rac racemic mixture RPMI Roswell Park Memorial Institute Medium RT Room temperature SCX Strong Cation Exchange SFC Supercritical Fluid Chromatography TAD transcription initiation domain TATU O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate TBAF Tetrabutylammonium fluoride TBTU 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethylammonium tetrafluoroborate TEA Triethylamine TFA Trifluoroacetic acid THF Tetrahydrofuran TLC Thin layer chromatography t RA Retention time uma unified atomic mass unit UV

[0072] Compound

[0073] In a first aspect, the present disclosure provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO 2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -C(O)NHR', -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CN groups, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 ) cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H, methyl and phenyl, and Wherein each R" is independently selected from -OH, methyl, optionally substituted with -OCF 3 Substituted phenyl and tetrahydrofuranyl; L 1 Selected from direct bond, -O-, -CH 2 - and -CH =; R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halo, -OH, oxo, -NH 2 、-NHMe、-NO 2 、-CN、-SF 5 、-SiMe 3 、-B(OH) 2 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -O(C 3 -C 6 )cycloalkyl, -SO 2 CH 3 、-NHC(O)Me、-NHC(O)OC(CH 3 ) 3 , phenyl, benzyl, 1-λ 6 -2-thiazolidine-1,1-dione and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3-C 6 ) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 The group substitution, And further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 optionally substituted at one ring atom with spirocyclic oxindolyl; L 2 Select from direct bonds, -CH 2 -、-CH 2 CH 2 -and-CH 2 O-, where L 2 (when present) optionally replaced by -NH 2 or methyl substitution; R 3 is selected from -H, halo, -OH, and methyl optionally substituted with -OH; R 4 Is -H or -NH 2 ; R 5 is -H or methyl; X is CH or N; Y is selected from CH, CF and N (provided that when Y is N, X is also N); E is selected from -C(O)-, -S(O) 2 - and -O- (provided that when E is -O-, X and Y are both CH); and n is 0, 1 or 2.

[0074] In an embodiment, the compound is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -C(O)NHR', -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CN groups, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 ) cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H, methyl and phenyl, and wherein each R" is independently selected from methyl, optionally substituted with -OCF 3 Substituted phenyl and tetrahydrofuranyl; L 1 Selected from direct bond, -O-, -CH 2 - and -CH =; R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halogen, -OH, -NH 2 、-NO 2 、-CN、-SF 5 、-B(OH) 2 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -SO 2 CH 3 , phenyl, benzyl, 1-λ 6-2-thiazolidine-1,1-dione and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 ) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 The group substitution, And further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 optionally substituted at one ring atom with spirocyclic oxindolyl; L 2 Select from direct bonds, -CH 2 -、-CH 2 CH 2 -and-CH 2 O-, where L 2 (when present) optionally replaced by -NH 2 or methyl substitution; R 3 is selected from -H, halo, -OH, and methyl optionally substituted with -OH; R 4 Is -H or -NH 2 ; R 5 is -H or methyl; X and Y are each independently selected from CH and N (provided that when Y is N, X is also N); E is selected from -C(O)-, -S(O) 2 - and -O- (provided that when E is -O-, X and Y are both CH); and n is 0, 1 or 2.

[0075] In an embodiment, the compound is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R1 Optionally one or more R A replace, Each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO 2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH and -NH 2 The group substitution, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 ) cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H and methyl, and wherein each R" is independently selected from -OH, methyl and tetrahydrofuranyl; L 1 Select from direct bonds and -CH 2 -; R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halo, -OH, oxo, -NH 2 、-NHMe、-NO 2 、-CN、-SF 5 、-SiMe 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6)cycloalkyl, -O(C 3 -C 6 )cycloalkyl, -SO 2 CH 3 、-NHC(O)Me、-NHC(O)OC(CH 3 ) 3 , phenyl, benzyl and 1-λ 6 -2-thiazolidine-1,1-dione, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 ) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 The group substitution, And further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 optionally substituted at one ring atom with spirocyclic oxindolyl; L 2 Select from direct bond, -CH 2 -and-CH 2 O-, where L 2 (when present) optionally substituted with methyl; R 3 is selected from -H and halo; R 4 Yes - H; R 5 is -H or methyl; X is CH or N; Y is CH or CF; E is selected from -C(O)- and -S(O) 2 -;and n is 0, 1 or 2.

[0076] In an embodiment, the compound is a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO 2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH and -NH 2 The group substitution, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 ) cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H and methyl, and wherein each R" is independently selected from methyl and tetrahydrofuranyl; L 1 Select from direct bonds and -CH 2 -; R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halogen, -OH, -NH 2 、-NO 2 、-CN、-SF 5 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6)cycloalkyl, -SO 2 CH 3 , phenyl, benzyl and 1-λ 6 -2-thiazolidine-1,1-dione, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 ) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 The group substitution, And further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 optionally substituted at one ring atom with spirocyclic oxindolyl; L 2 Select from direct bond, -CH 2 -and-CH 2 O-, where L 2 (when present) optionally substituted with methyl; R 3 is selected from -H and halo; R 4 Yes - H; R 5 is -H or methyl; X and Y are each independently selected from CH and N (provided that Y is not N); E is selected from -C(O)- and -S(O) 2 -;and n is 0, 1 or 2.

[0077] In an embodiment, the compound is a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , L 1 , X, Y and n are as defined herein.

[0078] In an embodiment, the compound is a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3, R 5 , L 1 and n are as defined herein.

[0079] In an embodiment, R 1 Selected from -H, -(C 1 -C 6 )alkyl, -(C 3 -C 7 )cycloalkyl, -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A Substitute, where each R A are independently selected from halo, -OH, -NHR', -CN, oxo, -SO 2 CH 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -C(O)R", -NHC(O)R", -(C 3 -C 6 )cycloalkyl, 3 to 6-membered heterocycloalkyl, phenyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -OH and -NH 2 The group substitution, and / or two of the R A Together with the atom or atoms to which they are attached, they can form (C 3 -C 6 )cycloalkyl or 3 to 6 membered heterocycloalkyl, wherein each R' is independently selected from -H and methyl, and wherein each R" is independently selected from -OH, methyl and tetrahydrofuranyl.

[0080] In an embodiment, R 1 Selected from -H, -(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -(C 5 -C 7 )cycloalkenyl, -(C 6 -C 10) aryl, 4- to 9-membered heterocycloalkyl, 6-membered heterocycloalkenyl, 5- to 6-membered heteroaryl, and 9- to 10-membered heteroaryl, wherein R 1 Optionally one or more R as defined herein A replace.

[0081] In an embodiment, R 1 is a 6- to 10-membered polycyclic (eg, bicyclic) heterocycloalkyl group or a 7- to 10-membered polycyclic (eg, bicyclic) heteroaryl group, wherein R 1 Optionally one or more R as defined herein A replace.

[0082] In an embodiment, R 1 is optionally replaced by one or more R as defined herein A substituted 6- to 10-membered polycyclic (eg, bicyclic) heterocycloalkyl. 1 is optionally replaced by one or more R A substituted 7 to 9 membered polycyclic (eg, bicyclic) heterocycloalkyl. 1 is a 7- to 9-membered bicyclic heterocycloalkyl group containing one or two (e.g., two) heteroatoms selected from nitrogen, oxygen and sulfur, wherein R 1 Optionally one or more R A replace.

[0083] In an embodiment, R 1 is optionally replaced by one or more R as defined herein A substituted 7- to 10-membered polycyclic (eg, bicyclic) heteroaryl. In one embodiment, R 1 is a 7- to 10-membered bicyclic heteroaryl group containing one or two (e.g., two) heteroatoms selected from nitrogen, oxygen and sulfur, wherein R 1 Optionally one or more R A In an embodiment, R 1 is a 9- or 10-membered bicyclic heteroaryl group containing one or two (e.g., two) heteroatoms selected from nitrogen and sulfur, wherein R 1 Optionally one or more R A In an embodiment, R 1 is optionally replaced by one or more R A substituted 8- to 9-membered (eg, 9-membered) polycyclic (eg, bicyclic) heteroaryl. In one embodiment, R 1 is an unsubstituted 9-membered bicyclic heteroaryl.

[0084] In an embodiment, R 1 is fully saturated. In other embodiments, R 1is partially or fully unsaturated (e.g., a partially or fully unsaturated cyclic group). 1 Selected from -(C 4 -C 8 )cycloalkenyl, 5- to 8-membered heterocycloalkenyl, -(C 6 -C 10 ) aryl and 9- to 10-membered heteroaryl, wherein R 1 Optionally one or more R as defined herein A In an embodiment, R 1 Yes-(C 4 -C 8 )cycloalkenyl or 5 to 8 membered heterocycloalkenyl, wherein R 1 Optionally one or more R A In an embodiment, R 1 Yes-(C 6 -C 10 ) aryl or 9- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A In an embodiment, R 1 is a 5- to 8-membered heterocycloalkenyl or a 9- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A In an embodiment, R 1 Yes-(C 4 -C 8 )cycloalkenyl or -(C 6 -C 10 ) aryl, wherein R 1 Optionally one or more R A replace.

[0085] In an embodiment, R 1 Selected from -(C 4 -C 8 )cycloalkenyl, -(C 6 -C 10 )aryl, 7 to 10-membered polycyclic (e.g., bicyclic) heterocycloalkyl, 5 to 8-membered heterocycloalkenyl, and 7 to 10-membered polycyclic (e.g., bicyclic) heteroaryl, wherein R 1 Optionally one or more R as defined herein A Substitution, or R 1 is one or more selected from -OH, -NH 2 and -O(C 1 -C 3 ) alkyl substituted-(C 1 -C 6 )alkyl.

[0086] In an embodiment, R1 Selected from: Where R 1 Optionally one or more R as defined herein A replace.

[0087] In an embodiment, R 1 Selected from: Where R 1 Optionally one or more R as defined above A In an embodiment, each R A Independently selected from -halo, -OH, -NH 2 , oxo, -(C 1 -C 3 )alkyl, -C(O)R" and -O(C 1 -C 3 )alkyl, wherein each (C 1 -C 3 ) alkyl may be optionally substituted with one or more halo groups, wherein each R" is independently selected from methyl, optionally substituted with -OCF 3 In other embodiments (e.g., wherein R 1 is a cycloalkyl group), R 1 By two R A Replace the two R A When taken together with the atom or atoms to which they are attached, they form a 3- to 6-membered heterocycloalkyl.

[0088] In an embodiment, R 1 Selected from:

[0089] In an embodiment, R 1 Selected from:

[0090] In an embodiment, R 1 Yes-(C 4 -C 6 )cycloalkyl or 5 to 7 membered heterocycloalkyl, wherein the heterocycloalkyl contains one or two atoms independently selected from O and N, and wherein the cycloalkyl or heterocycloalkyl is optionally and independently replaced by one or more R as defined above A In an embodiment, each RA Independently selected from -OH, -NH 2 , -Me, difluoroethyl and -OCH 3 .

[0091] In an embodiment, R 1 Selected from:

[0092] In other embodiments, R 1 Selected from:

[0093] In an embodiment, L 1 Is a direct bond or -CH 2 -. In an embodiment, L 1 is a direct bond. In other embodiments, L 1 Yes-CH 2 -.

[0094] In an embodiment, L 1 Is a direct bond or CH 2 -, and R 1 Yes-(C 4 -C 6 )cycloalkyl or 5 to 7 membered heterocycloalkyl, wherein the heterocycloalkyl contains one or two atoms independently selected from O and N, and wherein the cycloalkyl or heterocycloalkyl is optionally and independently replaced by one or more R as defined above A In an embodiment, each R A Independently selected from -OH, -NH 2 , -Me, difluoroethyl and -OCH 3 .

[0095] In an embodiment, L 1 Yes-CH 2 -, and R 1 Yes-(C 3 -C 7 ) cycloalkyl, 4- to 10-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R as defined herein A replace.

[0096] In the embodiment, when L 1 When it is -O-, R 1 Not -H.

[0097] In an embodiment, R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B Selected from halo, -OH, oxo, -NH 2 、-NHMe、-NO 2 、-CN、-SF 5 、-SiMe 3 、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -O(C 3 -C 6 )cycloalkyl, -SO 2 CH 3 、-NHC(O)Me、-NHC(O)OC(CH 3 ) 3 , phenyl, benzyl and 1-λ 6 -2-thiazolidine-1,1-dione, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -(C 3 -C 6 ) Each of cycloalkyl, phenyl and benzyl is optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 and further wherein, when R 2 Yes-(C 3 -C 6 ) cycloalkyl, R 2 Optionally substituted at one ring atom with spirocyclic oxindolyl.

[0098] In an embodiment, R 2 Selected from -(C 3 -C 6 )cycloalkyl, 5- to 6-membered heterocycloalkyl, 9- to 10-membered heterocycloalkyl, -(C 6 -C 10 ) aryl, 5- to 6-membered heteroaryl, and 9- to 10-membered heteroaryl, wherein R 2 Optionally one or more R as defined herein B replace.

[0099] In an embodiment, R 2 Selected from -(C 4 -C6 )cycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R as defined above B In an embodiment, each R B are independently selected from halo, -NO 2 、-NH 2 、-OCH 3 、-OCF 3 、-SF 5 , optionally substituted by one or more halogen groups -(C 1 -C 3 )alkyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl.

[0100] In an embodiment, R 2 Selected from -(C 5 -C 6 ) cycloalkyl, phenyl and 6 to 9 membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -NO 2 、-NH 2 、-OCH 3 、-OCF 3 、-SF 5 , optionally substituted by one or more fluorine-(C 1 -C 2 )alkyl and optionally -CF 3 Substituted cyclopropyl.

[0101] In an embodiment, R 2 Selected from: Where R 2 Optionally one or more R as defined herein B replace.

[0102] In an embodiment, R 2 is optionally replaced by one or more R as defined herein B Replaced-(C 3 -C 6 )cycloalkyl, further wherein R 2 Optionally substituted at one ring atom with spirocyclic oxindolyl.

[0103] In an embodiment, R BSelect from -NO 2 、-SF 5 、-SiMe 3 、-B(OH) 2 、-(C 3 -C 6 )cycloalkyl, -O(C 3 -C 6 ) cycloalkyl, phenyl and optionally substituted by one or more independently selected from halo, -OH, -NH 2 and -CF 3 substituted benzyl, wherein -(C 3 -C 6 ) Each of the cycloalkyl and phenyl groups is replaced by one or more independently selected from halo, -OH, -NH 2 and -CF 3 In the embodiment, R B Not -O(C 3 -C 6 ) cycloalkyl. In an embodiment, R B is not -O-cyclopropyl. In an embodiment, R B Not -NHC(O)OC(CH 3 ) 3 .

[0104] In an embodiment, at least one R B Yes-SF 5 In an embodiment, an R B Yes-SF 5 In an embodiment, R 2 By an R B Replace, and R B Yes-SF 5 In an embodiment, R 2 By two R B Replace one of the R B Yes-SF 5 , and another R B Selected from -F, -OH, -NH 2 , -NHMe and -NO 2 In an embodiment, R 2 By two R B Replace one of the R B Yes-SF 5 , and another R B Selected from -OH and -NH 2 In an embodiment, R 2 By two R B Replace one of the R B Yes-SF 5 , and another RB Yes-NH 2 .

[0105] In an embodiment, R 2 Is one or two R B substituted phenyl, and at least one R B Yes-SF 5 In an embodiment, R 2 Is one or two R B substituted phenyl, and one R B Yes-SF 5 In an embodiment, R 2 Is one or two R B Substituted phenyl, one of which R B Yes-SF 5 , and another R B (when present) selected from -F, -OH, -NH 2 , -NHMe and -NO 2 In an embodiment, R 2 Is one or two R B Substituted phenyl, one of which R B Yes-SF 5 , and another R B (when present) selected from -OH and -NH 2 In an embodiment, R 2 It is two R B Substituted phenyl, one of which R B Yes-SF 5 , and another R B Selected from -F, -OH, -NH 2 , -NHMe and -NO 2 In an embodiment, R 2 It is two R B Substituted phenyl, one of which R B Yes-SF 5 , and another R B Selected from -OH and -NH 2 In an embodiment, R 2 It is two R B Substituted phenyl, one of which R B Yes-SF 5 , and another R B Yes-NH 2 In an embodiment, R 2 is an R B substituted phenyl, and R B Yes-SF 5 .

[0106] In an embodiment, R 2 Selected from: Where R 2 Optionally one or more R as defined above B In an embodiment, each R B independently selected from halo, -NH 2 、-O(C 1 -C 3 )alkyl, -(C 1 -C 3 )alkyl, -(C 3 -C 6 )cycloalkyl, -SF 5 AND-NO 2 , where -O(C 1 -C 3 )alkyl, -(C 1 -C 3 )alkyl and -(C 3 -C 6 ) Each of the cycloalkyl groups is optionally substituted by one or more independently selected from halo and -CF 3 The group is substituted.

[0107] In an embodiment, R 2 Selected from:

[0108] In an embodiment, R 2 Selected from:

[0109] In an embodiment, R 2 Selected from: Where R 2 Optionally one or more R B Substitute, where each R B Independently selected from -NH 2 、-OCF 3 、-SF 5 and (C 1 -C 3 )alkyl.

[0110] In an embodiment, R 2 Selected from:

[0111] In an embodiment, R 2 Selected from:

[0112] In an embodiment, R 2 yes:

[0113] In an embodiment, R 2 yes

[0114] In other embodiments, R 2 yes

[0115] In an embodiment, R 2 yes:

[0116] In an embodiment, R 2 yes

[0117] In other embodiments, R 2 yes

[0118] In other embodiments, R 2 yes

[0119] In an embodiment, L 2 Select from direct bonds, -CH 2 -and-CH 2 O-, where L 2 (when present) is optionally substituted with methyl. In an embodiment, L 2 Selected from direct bonds, unsubstituted -CH 2 - and -CH substituted by methyl 2 O-.

[0120] In an embodiment, L 2 It is a direct key.

[0121] In an embodiment, L 2 is a direct key, and R 2 Selected from:

[0122] In an embodiment, L 2 is a direct key, and R 2 Selected from:

[0123] In an embodiment, L 2 is a direct key, and R 2 Selected from:

[0124] In an embodiment, L 2 is a direct key, and R 2 Selected from:

[0125] In an embodiment, L 2 is a direct key, and R 2 yes:

[0126] In an embodiment, L 2 is a direct key, and R 2 yes

[0127] In other embodiments, L 2 is a direct key, and R 2 yes

[0128] In an embodiment, L 2 is a direct key, and R 2 yes:

[0129] In an embodiment, L 2 is a direct key, and R 2 yes

[0130] In other embodiments, L 2 is a direct key, and R 2 yes

[0131] In other embodiments, L 2 is a direct key, and R 2 yes

[0132] In an embodiment, R 3 is -H or halo (e.g., -F). 3 is halo (e.g., -F). In an embodiment, R 3 Yes -F.

[0133] In an embodiment, R 3 is -H. In an embodiment, R 4 is -H. In an embodiment, R 3 and R4 Both are -H.

[0134] In an embodiment, R 3 is -H or a halide (eg, -F), and R 4 is -H. In an embodiment, R 3 is a halogen group (e.g., -F), and R 4 is -H. In an embodiment, R 3 Yes -F, and R 4 Yes -H.

[0135] In an embodiment, R 5 is -H. In an embodiment, R 3 , R 4 and R 5 All are -H.

[0136] In an embodiment, R 5 It's methyl.

[0137] In an embodiment, R 3 is a halogen group (e.g., -F), R 4 Yes -H, and R 5 is -H. In an embodiment, R 3 is a halogen group (e.g., -F), R 4 Yes -H, and R 5 is methyl. In an embodiment, R 3 Yes - F, R 4 Yes -H, and R 5 is -H. In an embodiment, R 3 Yes - F, R 4 Yes -H, and R 5 It's methyl.

[0138] In an embodiment, X is N.

[0139] In an embodiment, Y is CH.

[0140] In an embodiment, Y is CF. In an embodiment, X is N and Y is CF.

[0141] In an embodiment, E is -C(O)- or -S(O) 2 - In an embodiment, E is -C(O)-.

[0142] In an embodiment, n is 1. In an embodiment, n is 0 or 2. In an embodiment, n is 0. In an embodiment, n is 2.

[0143] In an embodiment, X is N and Y is CH. In an embodiment, X is N, Y is CH, and n is 1. In an embodiment, X is N, Y is CH, n is 1, and R 5 Yes -H.

[0144] In an embodiment, X is N, and E is -C(O)-. In an embodiment, X is N, Y is CH, and E is -C(O)-.

[0145] In an embodiment, X is N, Y is CH, R 5 is -H, n is 1, and E is -C(O)-.

[0146] In an embodiment, X is N, Y is CH, and n is 0. In an embodiment, X is N, Y is CH, n is 0, and R 5 In an embodiment, X is N, Y is CH, n is 0, E is -C(O)-, L 2 It is a direct key, R 4 Yes -H, and R 5 is -H. From this aspect, the present disclosure provides compounds of formula (IC) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and L 1 is as defined herein.

[0147] In an embodiment, X is N, Y is CH, and n is 2. In an embodiment, X is N, Y is CH, n is 2, and R 5 In an embodiment, X is N, Y is CH, n is 2, E is -C(O)-, L 2 is a direct key, R 4 Yes -H, and R 5 is -H. From this aspect, the present disclosure provides compounds of formula (ID) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and L 1 is as defined herein.

[0148] In an embodiment, R 1 is optionally replaced by one or more R A Substituted cyclohexyl or 4 to 7 membered heterocycloalkyl, wherein: each R A are independently selected from halo and (C1 -C 3 ) alkyl; L 1 Is a direct bond or -CH 2 -; R 2 yes L 2 is a direct bond; X is N, Y is CH, R 3 Yes - H, R 4 Yes - H, R 5 is H, n is 1, and E is -C(O)-.

[0149] In an embodiment, the compound is a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 , L 1 , R 3 , R 4 and R 5 is as defined above, and wherein: R 2 Selected from -(C 3 -C 6 )cycloalkyl (e.g., cyclopropyl), -(C 6 -C 10 ) aryl, 5- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -OH, oxo, -NO 2 、-NH 2 、-NHMe、-CN、-SF 5 、-SO 2 CH 3 、-NHC(O)Me、-NHC(O)OC(CH 3 ) 3 、-SiMe 3 , optionally substituted by one or more halogen groups -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, optionally substituted with -CF 3 Replaced-(C 3 -C 6 )cycloalkyl, -O-cyclopropyl, optionally substituted with one or more halo, -OH or -CF 3 substituted phenyl, benzyl optionally substituted by halogen, and 1-λ 6-2-thiazolidine-1,1-dione, And further wherein, when R 2 When it is cyclopropyl, R 2 is optionally substituted at one ring atom with spirocyclic oxindolyl; and E is -C(O)- or -S(O) 2 -.

[0150] In an embodiment, R 2 Selected from -(C 4 -C 6 )cycloalkyl, -(C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -NO 2 、-NH 2 、-OCH 3 、-OCF 3 、-SF 5 , optionally substituted by one or more halogen groups -(C 1 -C 3 )alkyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl.

[0151] In an embodiment, E is -C(O)-.

[0152] In an embodiment, the compound is a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein: R 1 Yes-H, -(C 1 -C 3 )alkyl, -(C 4 -C 6 )cycloalkyl, -(C 5 -C 7 )cycloalkenyl, -(C 6 -C 10 ) aryl or 4 to 9 membered heterocycloalkyl, 6 membered heterocycloalkenyl, 5 to 6 membered heteroaryl and 9 to 10 membered heteroaryl, wherein R 1 Optionally one or more R A Substitute, where each R A are independently selected from halo, -OH, oxo, -NH 2 , -NHMe, -C(O)OH, -C(O)Me, -SO2 CH 3 、-NHC(O)R”、-(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, cyclopropyl, oxetanyl, sulfolane, phenyl, benzyl and pyridyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) Each of the alkyl and phenyl species is optionally substituted by one or more independently selected from halo, -OH and -NH 2 The group substitution, wherein each R" is independently selected from methyl and tetrahydrofuranyl; L 1 Is a direct bond or -CH 2 -;and R 2 Selected from -(C 3 -C 6 )cycloalkyl, -(C 6 -C 10 ) aryl, 5- to 6-membered heterocycloalkyl, and 5- to 10-membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -NO 2 、-NH 2 , -NHMe, -NHAc, -NHBoc, -O(C 1 -C 3 ) alkyl, -SF 5 、-SiMe 3 、-(C 1 -C 3 )alkyl, -O-cyclopropyl, 1-λ 6 -2-thiazolidine-1,1-dione, phenyl, benzyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl, phenyl and benzyl are each optionally substituted by one or more independently selected from halo, -NH 2 and -CF 3 -substituted with a group, and further wherein, when R 2 When it is cyclopropyl, R 2 Optionally substituted at one ring atom with spirocyclic oxindolyl.

[0153] In an embodiment, R 2 Selected from -(C 4 -C 6 )cycloalkyl, (C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -NO 2 、-NH 2 、-OCH 3 、-OCF 3 、-SF 5 , optionally substituted by one or more halogen groups (C 1 -C 3 )alkyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl.

[0154] In an embodiment, the compound is a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein: R 1 is optionally replaced by one or more R A Substituted cyclohexyl or 4 to 7 membered heterocycloalkyl, wherein each R A are independently selected from halo and (C 1 -C 3 )alkyl; L 1 Is a direct bond or -CH 2 -;and R 2 Selected from -(C 4 -C 6 )cycloalkyl, (C 6 -C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B are independently selected from halo, -NO 2 、-NH 2 、-OCH 3 、-OCF 3 、-SF 5 , optionally substituted by one or more halogen groups (C 1 -C 3 )alkyl and optionally -CF 3 Replaced-(C 3 -C6 )cycloalkyl.

[0155] In an embodiment, R 2 Selected from:

[0156] In an embodiment, L 2 is a direct key, and R 2 Selected from:

[0157] In an embodiment, L 2 is a direct key, and R 2 Selected from:

[0158] In other embodiments, L 2 is a direct key, and R 2 yes:

[0159] In other embodiments, L 2 is a direct key, and R 2 yes

[0160] In an embodiment, R 2 yes:

[0161] In an embodiment, R 2 yes

[0162] In an embodiment, R 2 yes

[0163] In other embodiments, R 2 yes

[0164] In an embodiment, the compound is a compound of formula (IV) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined above, and wherein: p is 1, 2, 3, 4, or 5; and Each R B are independently selected from halo, -NO 2 、-NH 2, -NHMe, -NHAc, -NHBoc, -OCH 3 、-OCF 3 、-SF 5 、SiMe 3 , (C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, -O-cyclopropyl, 1-λ 6 -2-thiazolidine-1,1-dione, phenyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl, wherein -(C 1 -C 3 )alkyl, -O(C 1 -C 3 ) alkyl and phenyl are each optionally substituted by one or more independently selected from halo, -NH 2 and -CF 3 The group is substituted.

[0165] In an embodiment, p is 1 or 2; and each R B are independently selected from halo, -NO 2 、-NH 2 、-OCH 3 、-OCF 3 、-SF 5 , optionally substituted by one or more halogen groups (C 1 -C 3 )alkyl and optionally -CF 3 Replaced-(C 3 -C 6 )cycloalkyl.

[0166] In embodiments, p is 1, 2 or 3. In embodiments, p is 1 or 2. In embodiments, p is 1. In other embodiments, p is 2. In other embodiments, p is 3.

[0167] In an embodiment, p is 1 or 2, and each R B Independently selected from halo, -OH, -OCF 3 、-NH 2 , -NHMe, -NHAc and -SF 5 In an embodiment, p is 1 or 2, and each R B Independently selected from halo, -OH, -OCF 3 、-NH 2 and-SF 5 .

[0168] In an embodiment, each R B Independently selected from -OCF 3 、-NH 2 and-SF 5 , and p is 1 or 2.

[0169] In an embodiment, p is 3, 4 or 5. In an embodiment, p is 3, 4 or 5, and at least one R B is halo (eg, -F). In an embodiment, p is 4 or 5, and 4 R B is halo (eg, -F). In an embodiment, p is 4 or 5, and 4 R B Yes -F.

[0170] In an embodiment, the compound is a compound of formula (V) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined above, and wherein: R B1 is -H, or is selected from halo (e.g., -F or -Cl), -OH, -NH 2 , -NHMe, -NHAc, -NHBoc and -NO 2 ;and R B2 Selected from halide (e.g. -Br), -SF 5 、-SO 2 CH 3 、-SiMe 3 , optionally substituted by one or more halogen groups -(C 1 -C 3 )alkyl, -O(C 1 -C 3 )alkyl, 1-trifluoromethylcycloprop-1-yl, -O-cyclopropyl and optionally substituted by one or more independently selected from halo or -NH 2 A phenyl group substituted with a group.

[0171] In an embodiment, R B1 is -H, or is selected from -NH 2 AND-NO 2 ; and R B2 Selected from -OCF 3 、-SF 5 , -CF 2 CF 3 、-CH 2 CF 3 and 1-trifluoromethylcyclopropan-1-yl.

[0172] In an embodiment, R B1 is -H, or is selected from halo (e.g., -F), -NH 2 , -NHMe, -NHAc and -OH; and R B2 Selected from -OCF 3 and-SF 5 .

[0173] In an embodiment, R B2 Yes-SF 5 In an embodiment, R B1 is -H, or is selected from halo (e.g., -F), -NH 2 、-NHMe、-NO 2 and -OH; and R B2 Yes-SF 5 In an embodiment, R B1 is -H, or is selected from halo (e.g., -F), -NH 2 , -NHMe and -OH; and R B2 Yes-SF 5 .

[0174] In an embodiment, the compound is a compound of formula (VI) or (VII) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 5 , n and L 1 is as defined above.

[0175] In embodiments, the compound is a compound of formula (VI) or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of formula (VII) or a pharmaceutically acceptable salt thereof.

[0176] In an embodiment, the compound is a compound of formula (VI-A) or (VII-A) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined above.

[0177] In an embodiment, L 1 Yes-CH 2 -. In other embodiments, L 1 It is a direct key.

[0178] In embodiments, the compound is a compound of formula (VI-A) or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of formula (VII-A) or a pharmaceutically acceptable salt thereof.

[0179] In an embodiment, the compound is a compound of formula (VIII), (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 5 and n are as defined above.

[0180] In embodiments, the compound is a compound of formula (VIII) or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of formula (IX) or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of formula (X) or a pharmaceutically acceptable salt thereof.

[0181] In an embodiment, the compound is a compound of formula (VIII-A), (IX-A) or (XA) or a pharmaceutically acceptable salt thereof, wherein R 1 is as defined above.

[0182] In embodiments, the compound is a compound of formula (VIII-A) or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of formula (IX-A) or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is a compound of formula (XA) or a pharmaceutically acceptable salt thereof.

[0183] In an embodiment, the compound is as defined herein (eg, a compound of Formula (I) or a pharmaceutically acceptable salt thereof), provided that if R B Yes-O(C 3 -C 6 )cycloalkyl or -NHBoc, then R 1 No - (C 3 -C 6 )cycloalkyl or 4 to 6 membered monocyclic heterocycloalkyl. In an embodiment, the compound is as defined herein (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof), provided that if R B is -O-cyclopropyl or -NHBoc, then R 1is not cyclopropyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or piperidinyl. In an embodiment, the compound is as defined herein (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof), provided that if R B is -O-cyclopropyl, then R 1 no In an embodiment, the compound is as defined herein (eg, a compound of Formula (I) or a pharmaceutically acceptable salt thereof), provided that if R B is -NHBoc, then R 1 no

[0184] In an embodiment, the compound (e.g., a compound of formula (I)) is not as defined in WO 2022 / 187518A1. In an embodiment, the compound (e.g., a compound of formula (I)) is not one or more (e.g., any) of the compounds exemplified in WO 2022 / 187518A1.

[0185] In embodiments, the compound (eg, a compound of Formula (I)) is not one or more (eg, any) of the following: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -5-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one, -[4-(3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-[(2R)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -5-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2-amino-4-trifluoromethoxyphenyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(1-phenyl-4-pyrazolyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(2-amino-4-trifluoromethoxyphenyl)[4-(2-cyclopropyl-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -5-{7-[1-(2-amino-4-trifluoromethoxybenzoyl)-4-piperidinyl]-imidazo[4,5-b]pyridin-2-yl}-2-piperidinone; -(2-amino-4-chlorophenyl){4-[2-(2-morpholinyl)-3H-1,3,4-triazaindan-7-yl]-1-piperidinyl}methanone; -5-{7-[1-(2-amino-4-chlorobenzoyl)-4-piperidinyl]-3H-1,3,4-triazaindan-2-yl}-2-piperidinone; -(2-amino-4-chlorophenyl){4-[2-(3-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -6-{7-[1-(4-trifluoromethoxy-benzoyl)-4-piperidinyl]-imidazo[4,5-b]pyridin-2-yl}-3-morpholinone; -6-{7-[1-(2-amino-4-chlorobenzoyl)-4-piperidinyl]-3H-1,3,4-triazaindan-2-yl}-3-morpholinone; -3-({4-[2-(tetrahydro-2H-pyran-4-yl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}carbonyl)-6-(trifluoromethyl)-2(1H)-pyridinone; -(2-amino-4-trifluoromethoxyphenyl){4-[2-(1-methyl-3-pyrrolidinyl)-3H-1,3,4-triazaindan-7-yl]-1-piperidinyl}methanone; -6-{7-[1-(2-amino-4-trifluoromethoxy-benzoyl)-4-piperidinyl]-imidazo[4,5-b]pyridin-2-yl}-3-morpholinone; -(2-amino-4-trifluoromethoxyphenyl){4-[6-fluoro-2-(1-methyl-4-pyrazolyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(2-amino-4-chlorophenyl){4-[6-fluoro-2-(1-methyl-4-pyrazolyl)-3H-1,3,4-triazaindan-7-yl]-1-piperidinyl}methanone; -5-{7-[1-(2-amino-4-chlorobenzoyl)-4-piperidinyl]-6-fluoro-3H-1,3,4-triazaindan-2-yl}-2-piperidinone; -6-{7-[1-(2-amino-4-trifluoromethoxybenzoyl)-4-piperidinyl]-6-fluoro-imidazo[4,5-b]pyridin-2-yl}-3-morpholinone; -3-{[4-(6-fluoro-3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]carbonyl}-6-(trifluoromethyl)-2(1H)-pyridinone; -3-({4-[6-fluoro-2-(tetrahydro-2H-pyran-4-yl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}carbonyl)-6-(trifluoromethyl)-2(1H)-pyridinone; -4-{[4-(6-fluoro-3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]carbonyl}-1-(2,2,2-trifluoroethyl)-2(1H)-pyridinone; -3-{[4-(6-fluoro-3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]carbonyl}-1-methyl-6-(trifluoromethyl)-2(1H)-pyridinone; -{4-[6-fluoro-2-(1-methyl-4-pyrazolyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}(p-trifluoromethoxyphenyl)methanone; -(2-amino-4-trifluoromethoxyphenyl){4-[6-fluoro-2-(3-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(2-amino-4-chlorophenyl){4-[6-fluoro-2-(3-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-trifluoromethoxyphenyl){4-[6-fluoro-2-(2-morpholinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(2-amino-4-chlorophenyl){4-[6-fluoro-2-(2-morpholinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -6-{7-[1-(2-amino-4-chlorobenzoyl)-4-piperidinyl]-6-fluoro-3H-1,3,4-triazaindan-2-yl}-3-morpholinone; -(2-amino-4-chloro-5-fluorophenyl){4-[6-fluoro-2-(1-methyl-4-pyrazolyl)-3H-1,3,4-triazaindan-7-yl]-1-piperidinyl}methanone; -4-{7-[1-(2-amino-4-trifluoromethoxy-benzoyl)-4-piperidinyl]-6-fluoro-imidazo[4,5-b]pyridin-2-yl}-1λ 6 -1,1-sulfide cyclopentanedione (thianedione); -{4-[6-fluoro-2-(tetrahydro-2H-pyran-4-yl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}(4-trifluoromethoxyphenyl)methanone; -(6-indolyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -{4-[6-fluoro-2-(3-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}(4-trifluoromethoxyphenyl)methanone; -1-(4-{7-[1-(2-amino-4-trifluoromethoxy-benzoyl)-4-piperidinyl]-6-fluoro-imidazo[4,5-b]pyridin-2-yl}-1-piperidinyl)-1-ethanone; -(2-amino-4-trifluoromethoxyphenyl){4-[6-fluoro-2-(4-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(2-amino-4-chloro-5-fluorophenyl){4-[6-fluoro-2-(1-methyl-4-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-chloro-5-fluorophenyl){4-[6-fluoro-2-(4-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-chloro-5-fluorophenyl){4-[6-fluoro-2-(3-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-trifluoromethoxyphenyl){4-[6-fluoro-2-(3-fluoro-1-methyl-4-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-trifluoromethoxyphenyl){4-[6-fluoro-2-(1-methyl-4-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -{4-[6-fluoro-2-(3-oxetanyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}(p-trifluoromethoxyphenyl)methanone; -{4-[6-fluoro-2-(2-morpholinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}(p-trifluoromethoxyphenyl)methanone; -{4-[6-fluoro-2-(4-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}(p-trifluoromethoxyphenyl)methanone; -7-[1-(2-amino-4-chlorobenzoyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; -7-[1-(4-trifluoromethoxy-benzoyl)-4-piperidinyl]-imidazo[4,5-b]pyridin-2-one; -7-[1-(2-amino-4-trifluoromethoxy-benzoyl)-4-piperidinyl]-imidazo[4,5-b]pyridin-2-one; -(6-indolyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(1-methyl-1H-indazol-5-yl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(4-amino-3-methyl-5-isothiazolyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(5-bromo-2-pyrimidinyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(4-hydroxy-7-methyl-1,8-diaza-3-naphthyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl][5-(trifluoromethyl)-3-pyrazolyl]methanone; -(3-amino-4-bromo-5-fluorophenyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -[1-(tert-butyl)-3-pyrrolyl][4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(1-methyl-4-imidazolyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -7-[1-(2-naphthylsulfonyl)-4-piperidinyl]-3H-1,3,4-triazaindene; -7-[1-(4-methoxyphenylsulfonyl)-4-piperidinyl]-3H-1,3,4-triazaindene; -7-[1-(5-methyl-2-thienylsulfonyl)-4-piperidinyl]-3H-1,3,4-triazaindene; -7-{1-[m-(trifluoromethyl)phenylsulfonyl]-4-piperidinyl}-3H-1,3,4-triazaindene; -(6-methyl-2-naphthyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -(3-amino-2-naphthyl){4-[2-(trifluoromethyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(5-cyclopentyl-2-thienyl)[4-(3H-1,3,4-triazaindene-7-yl)-1-piperidinyl]methanone; -7-{1-[(3-quinolyl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-{1-[(6-isoquinolyl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-{1-[(2-quinolyl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-{1-[(1,3-benzothiazol-6-yl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-[1-(5-ethyl-2-thenoyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; -7-[3-hydroxy-1-(5-isopropyl-3-thenoyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; -7-[1-(2,4-difluoro-3-anisyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; -7-{1-[(2-methyl-1,3-thiazol-5-yl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-{1-[(3-methoxy-5-isoxazolyl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-[1-(2-hydroxy-4,6-dimethyl-nicotinyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; -6-fluoro-7-{1-[(2-methyl-1H-1,3-benzimidazol-6-yl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -2-[4-(2-oxo-1,3-dihydro-1,3,4-triaza-7-indenyl)-1-piperidinylsulfonyl]benzonitrile; -7-[1-(phenylsulfonyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; -7-{1-[(4-oxo-3-1H-quinolyl)carbonyl]-4-piperidinyl}-1,3-dihydro-1,3,4-triaza-2-indanone; -7-[1-(5-cyclopropyl-2-thenoyl)-4-piperidinyl]-1,3-dihydro-1,3,4-triaza-2-indanone; and -7-(1-{[1-(4-pyridinyl)-3-pyrazolyl]carbonyl}-4-piperidinyl)-1,3-dihydro-1,3,4-triaza-2-indanone.

[0186] In embodiments, the compound (eg, a compound of Formula (I)) is not one or more (eg, any) of the following: -(2-amino-4-cyclopropyloxyphenyl){4-[6-fluoro-2-(1-methyl-3-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-cyclopropyloxyphenyl){4-[6-fluoro-2-(3-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(4-cyclopropyloxyphenyl){4-[6-fluoro-2-(4-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(4-cyclopropyloxyphenyl){4-[6-fluoro-2-(1-methyl-4-piperidinyl)-3H-1,3,4-triazaindane-7-yl]-1-piperidinyl}methanone; -(2-amino-4-cyclopropyloxyphenyl){4-[6-fluoro-2-(4-piperidinyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(4-cyclopropyloxyphenyl){4-[6-fluoro-2-(tetrahydro-3-furyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -(4-cyclopropyloxyphenyl){4-[6-fluoro-2-(3-oxetanyl)-3H-1,3,4-triazaindene-7-yl]-1-piperidinyl}methanone; -tert-butyl N-(2-[4-[2-(oxan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carbonyl]-5-(trifluoromethoxy)phenyl)carbamate; and -tert-Butyl N-[2-(4-[2-cyclopropyl-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carbonyl)-5-(trifluoromethoxy)phenyl]carbamate.

[0187] In an embodiment, the compound is selected from: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, - trans-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-aminocyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -1-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]azetidin-1-yl]ethanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -5-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one, -[4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(azetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(4-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-[1-(2,2-difluoroethyl)azetidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(4-chloro-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-nitro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(4-methoxy-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -6-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-3-(trifluoromethyl)-1H-pyridin-2-one, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)phenyl]methanone, -[4-(trifluoromethoxy)phenyl]-[4-[2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(3-methoxy-1-bicyclo[1.1.1]pentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]methanone, -[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-pyrrolidin-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-[(1-methyl-4-piperidinyl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and -[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and pharmaceutically acceptable salts thereof.

[0188] In an embodiment, the compound is selected from: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, - trans-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-aminocyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -1-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]azetidin-1-yl]ethanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(azetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(4-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-[1-(2,2-difluoroethyl)azetidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(4-chloro-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-nitro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(4-methoxy-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -6-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-3-(trifluoromethyl)-1H-pyridin-2-one, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)phenyl]methanone, -[4-(trifluoromethoxy)phenyl]-[4-[2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(3-methoxy-1-bicyclo[1.1.1]pentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]methanone, -[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-pyrrolidin-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-[(1-methyl-4-piperidinyl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and -[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and pharmaceutically acceptable salts thereof.

[0189] In an embodiment, the compound is selected from: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-naphthyl-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -1H-indazol-3-yl-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]methanone; -(1-methyl-5-phenyl-pyrazol-3-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3-amino-2-naphthyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-3,4,5,6-tetrafluoro-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[1-isopropyl-2-(trifluoromethyl)benzimidazol-5-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-4-methylsulfonyl-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-(3-hydroxyphenyl)cyclopropyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[2-chloro-4-(trifluoromethyl)phenoxy]-1-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]propan-1-one; -(3-phenylcyclopentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-hydroxy-1-[2-(trifluoromethyl)phenyl]pyrazol-3-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[3-amino-4-phenyl-5-(trifluoromethyl)-2-thienyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(7-hydroxy-1H-indol-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -1-[4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1-piperidinyl]ethanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)cyclohexyl]methanone; -1-[4-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1-piperidinyl]ethanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]benzothiophene-5-carbonitrile; -(5-amino-1-phenyl-pyrazol-4-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[2-oxo-2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]ethyl]-4H-1,4-benzoxazin-3-one; -1-(3,4-difluorophenyl)-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -[4-(3-chloro-4-fluoro-phenyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(7-amino-2-methyl-pyrazolo[1,5-a]pyrimidin-6-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -1-[(2-chlorophenyl)methyl]-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -1-(4-fluorophenyl)-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -[1-[(2-chlorophenyl)methyl]pyrazol-4-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-aminophenyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3,6-dichloroimidazo[1,2-a]pyridin-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(4-amino-1-ethyl-pyrazol-3-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3-aminoquinoxalin-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]spiro[cyclopropane-1,3'-indolin]-2'-one; -[1-(2-chlorophenyl)pyrrolidin-3-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-4,5-dichloro-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[1-(4-fluorophenyl)imidazol-4-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3-amino-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)cyclohexyl]methanone; -[3-Fluoro-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(4-methylpiperazin-1-yl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[2-(5-chloro-2-hydroxy-phenyl)thiazol-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-fluoro-5-hydroxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]phenyl]tetrahydrofuran-2-carboxamide; -[4-[2-[5-(hydroxymethyl)isoxazol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -1-ethyl-3-hydroxy-6-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]quinoxalin-2-one; -[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -(4-bromophenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,4-dioxan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -4-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclohexanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-(4-trimethylsilylphenyl)methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2,2-difluoro-1,3-benzodioxol-5-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(4-bromo-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-(trifluoromethyl)-1H-indol-6-yl]methanone; -[4-(Cyclopropyloxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -2-tetrahydropyran-4-yl-7-[1-[4-(trifluoromethoxy)phenyl]sulfonyl-4-piperidinyl]-3H-imidazo[4,5-b]pyridine; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[rac-(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[1-(oxetan-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(oxetan-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-3-fluoro-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[rac-(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)cyclohexyl]-[4-(trifluoromethoxy)-1-piperidinyl]methanone; -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)cyclohexyl]-[4-(trifluoromethoxy)-1-piperidinyl]methanone; -[4-[2-(4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclopent-3-en-1-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2-amino-4-bromo-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-5-(trifluoromethoxy)phenyl]acetamide; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,6-tetrahydropyridin-5-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-phenylpyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-fluoropyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-amino-3,3,3-trifluoro-propyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[6-(aminomethyl)-3-pyridinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[rac-(3R,4S)-4-(4-pyridinyl)pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-2-bicyclo[2.2.1]hept-5-enyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-2-thienyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidine-4-carbonitrile; -[4-[2-[2-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-aminotetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,4-tetrahydroisoquinolin-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-5-hydroxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1H-indol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(azetidin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone 2,2,2-trifluoroacetate -[4-[2-(3-oxa-9-azabicyclo[3.3.1]non-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-amino-3-pyridinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[piperazin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-aminocyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[3-(methylamino)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-azabicyclo[4.1.0]hept-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-hydroxy-6-(trifluoromethyl)-3-quinolyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-oxabicyclo[3.1.0]hexan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[4-hydroxy-2-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]phenyl]acetamide; -5,6-dimethyl-3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyridin-2-one; -1-[3,5-dimethyl-4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyrrol-2-yl]ethanone; -[4-[2-[1-(1,1-dioxothiol-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1-methylsulfonylazetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-hydroxy-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1,4-oxazepan-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(1,1,2,2-tetrafluoroethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[rac-(1S,3S)-3-aminocyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclopent-3-en-1-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(azepan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-hydroxyphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[rac-(1R,3S)-3-aminocyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-(3-fluoro-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,6-tetrahydropyridin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]bicyclo[1.1.1]pentane-1-carboxylic acid; -3-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-6-(trifluoromethyl)-1H-pyridin-2-one; -[4-(difluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,1-dioxothiol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(trans)-4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclohexanecarboxylic acid; -(cis)-[4-[2-[3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,1-dioxothiol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-hydroxy-4-methyl-cyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-hydroxy-4-methyl-cyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,2,3,6-tetrahydropyridin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[Azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone hydrochloride; -[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-N-morpholinyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-(methylamino)-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -3-methyl-3-[7-[1-[4-(pentafluoro-λ 6-sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclobutanone; -[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[(cis)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[(trans)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-fluoro-4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6-sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(cis)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(trans)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6-sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]octan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]octan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-fluoro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[4-(hydroxymethyl)-1-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-thiomorpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -5-[6-fluoro-7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one; -(trans)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[4-(2-cyclopentyl-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclopentyl-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-5-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-(4-(6-fluoro-2-(4-hydroxy-4-methylcyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperidin-1-yl)(4-(pentafluoro-λ 6 -sulfuryl)phenyl)methanone; -(cis)-[4-[6-fluoro-2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-[6-fluoro-2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6-sulfanyl)phenyl]methanone; -4-(6-fluoro-2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3,4,4a,5,7,7a-hexahydro-2H-furo[3,4-b][1,4]oxazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-[6-fluoro-7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2,3,4a,5,7,7a-hexahydrofuro[3,4-b][1,4]oxazine-4-carboxylic acid; -[4-[2-(1,1-dioxo-1,4-thiazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; and -7-[6-fluoro-7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2-oxa-5-azaspiro[3.5]nonane-5-carboxylic acid, and pharmaceutically acceptable salts thereof.

[0190] In embodiments where the compound has enantiomeric forms (e.g., where the compound has a chiral center (e.g., a chiral carbon atom), the compound exists as a racemic mixture of enantiomers. In embodiments where the compound has a chiral center (e.g., a chiral carbon atom), the compound exists as an (R) isomer. In other embodiments where the compound has a chiral center (e.g., a chiral carbon atom), the compound exists as an (S) isomer. Thus, in embodiments, the compound is selected from: -(R)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(S)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(R)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(S)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(racemic)-5-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(R)-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(R)-[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(R)-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(racemic)-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(R)-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-[2-(4-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(racemic)-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(rac)-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(racemic)-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-(2-pyrrolidin-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, and -(racemic)-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and pharmaceutically acceptable salts thereof.

[0191] In an embodiment, the compound is selected from: -(R)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(S)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(R)-[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(R)-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(racemic)-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(R)-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(S)-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-[2-(4-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(racemic)-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(rac)-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(racemic)-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(racemic)-[4-(2-pyrrolidin-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, and -(racemic)-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and pharmaceutically acceptable salts thereof.

[0192] In an embodiment, the compound is selected from: -[4-[2-[(2R)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2S)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3R)-pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3S)-pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2R)-tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2S)-tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(3R)-5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3S)-5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,4-dioxan-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(rac)-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2R)-1,4-dioxan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2S)-1,4-dioxan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3R)-5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3S)-5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[(3R)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[(3S)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(4R)-oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(4S)-oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[(3S)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[(3R)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(2S)-6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2R)-6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2R)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2S)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(rac)-[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2S)-6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2R)-6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3R)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3S)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(rac)-[4-[2-(4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(rac)-[4-[2-(4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3R,4S)-4-phenylpyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2R,4S)-4-fluoropyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(2-amino-3,3,3-trifluoro-propyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2S)-pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2R)-2-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(2-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2R)-pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(azetidin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(3-oxa-9-azabicyclo[3.3.1]non-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2R)-piperazin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(2-azabicyclo[4.1.0]hept-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(3-oxabicyclo[3.1.0]hexan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone -(rac)-[4-[2-(1,4-oxazepan-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(6S)-7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(6R)-7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(6R)-7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(6S)-7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(azepan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone -[4-[2-[(3S)-4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3R)-4-amino-1-methyl-2-oxabicyclo[2.1.1]hexan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -(rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(rac)-[4-[2-(3-fluoro-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3S)-1,1-dioxothiol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3R)-1,1-dioxothiol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(2R)-1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2S)-1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2R)-1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(2S)-1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[(4R)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[(4S)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[(4R)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[(4S)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-[(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(2S,3R)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(rac)-[4-[2-(1,1-dioxothiol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3S)-azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[(3R)-azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3S)-azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[(3R)-azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6-sulfuryl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(2S)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(2R)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(3R)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(3S)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(2R)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(3R)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(3S)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(2S)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(2S)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(2S)-4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(2R)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(2R)-4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[(4S)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[(4R)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[(2R,4R)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[(2S,4S)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[(2R,4S)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[(2S,4R)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -(racemic)-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(2S,4S)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(2R,4R)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(2S,4R)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(2R,4S)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[(4S)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[(4R)-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6-sulfanyl)phenyl]-[(3R)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(3S)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(3R)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(3S)-3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -(racemic)-[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(rac)-[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(racemic)-[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(racemic)-[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[(2R,6R)-6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(racemic)-[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(rac)-[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[(1R,3R)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[(1S,3S)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[(1S,3R)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[(1R,3S)-(3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[4-(6-fluoro-2-thiomorpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(3S)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(3R)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(2R,6R)-6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(3S)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(3R)-tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[(2R)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(2S)-morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-5-[6-fluoro-7-[1-[4-(pentafluoro-λ 6-sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(1R,3S)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(1S,3R)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(1R,3R)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[(1S,3S)-3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[(4S)-oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(4R)-oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(4S)-oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[6-fluoro-2-[(4R)-oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(2R)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(2S)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[(2R)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(2S)-tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(2R)-tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[(2S)-tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(racemic)-[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(2R)-tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[(2S)-tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-[4-[2-(3,4,4a,5,7,7a-hexahydro-2H-furo[3,4-b][1,4]oxazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(racemic)-2-[6-fluoro-7-[1-[4-(pentafluoro-λ 6-sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2,3,4a,5,7,7a-hexahydrofuro[3,4-b][1,4]oxazine-4-carboxylic acid; -(rac)-[4-[2-(1,1-dioxo-1,4-thiazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; and -(rac)-7-[6-fluoro-7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2-oxa-5-azaspiro[3.5]nonane-5-carboxylic acid, and pharmaceutically acceptable salts thereof.

[0193] In an embodiment, the compound is selected from the compounds produced in Examples 1 to 461 (i.e., selected from Compounds 1-461) and pharmaceutically acceptable salts thereof. In other embodiments, the compound is selected from compounds obtainable by the synthetic method described in any one of Examples 1 to 461 (i.e., a method for synthesizing Compounds 1-461) and pharmaceutically acceptable salts thereof. In an embodiment, the compound is selected from the compounds produced in Examples 1 to 68 (i.e., selected from Compounds 1-68) and pharmaceutically acceptable salts thereof. In other embodiments, the compound is selected from compounds obtainable by the synthetic method described in any one of Examples 1 to 68 (i.e., a method for synthesizing Compounds 1-68) and pharmaceutically acceptable salts thereof.

[0194] In an embodiment, the compound is selected from Examples 70, 75, 97, 98, 101, 121, 131, 133, 150, 151, 156, 170, 173, 174, 178, 184, 185, 188, 189, 197, 198, 199, 204, 222, 257, 297, 302, 305, 308, 311, 314, 316, 318, 319, 328, 331, 334, 335, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380 44, 346, 349, 350, 356, 357, 364, 365, 366, 372, 379, 381, 382, ​​385, 392, 398, 399, 403, 404, 405, 409, 416, 418, 420, 423, 426, 427, 428, 429, 432, 433, 435, 436, 437, 443, 444, 447, 451, 453, 458, 459 and 460 compounds. In an embodiment, the compound is selected from the group consisting of compounds of Examples 97, 98, 121, 133, 150, 156, 173, 178, 199, 204, 257, 349, 350, 356, 364, 365, 366, 372, 381, 382, ​​392, 398, 405, 426, 427, 428, 432, 436, 437, 443, 447, 451, and 460. In an embodiment, the compound is selected from the group consisting of compounds of Examples 70, 75, 101, 131, 151, 170, 174, 184, 185, 188, 189, 197, 198, 222, 297, 302, 305, 308, 311, 314, 316, 318, 319, 328, 331, 334, 335, 343, 344, 346, 357, 379, 385, 399, 403, 404, 409, 416, 418, 420, 423, 429, 433, 435, 444, 453, 458, and 459.

[0195] In an embodiment, a compound of the present disclosure is characterized according to its inhibitory activity against ERK5 (e.g., as measured according to a cell-based assay or a cell-free assay as described in the Examples below). In an embodiment, the IC of the compound against ERK5 is 50 In one embodiment, the compound has an IC value of less than about 5 μM for ERK5. 50 The value is less than about 2 μM, (eg, less than about 1 μM, 0.5 μM, 0.2 μM, 100 nM, or 50 nM) (eg, when measured according to the cell-free assay described below).

[0196] In an embodiment, the compound is selected from the group consisting of compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, and 68. In an embodiment, the compound is selected from the group consisting of compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, and 68. In other embodiments, the compound is selected from the compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 42, 43, 44, 45, 46, 47, 50, 51, 53, 54, 56, 57, 61, 62, 63, 65, 67, and 68. In other embodiments, the compound is selected from the compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 36, 37, 39, 42, 43, 44, 46, 47, 50, 51, 53, 56, 57, 61, 62, 63, 65, 67, and 68. In other embodiments, the compound is selected from the compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 22, 23, 24, 25, 26, 27, 28, 29, 34, 36, 37, 43, 44, 47, 50, 51, 57, 63, 65, 67, and 68. In other embodiments, the compound is selected from the compounds 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 22, 29, 37, 44, 51, 57, 63, and 65. In other embodiments, the compound is selected from the compounds 3, 4, 5, 9, 12, 13, 22, 29, 37, 44, and 65.

[0197] In an embodiment, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 80, 81, 82, 83, 84 ,86,88,90,91,93,94,95,96,97,98,99,100,101,102,103,104,105,106,108,112,113,114,116,118,119,120,121,122,123,124,125,126,127,128 、129、130、131、132、133、134、136、137、138、140、141、142、143、144、145、146、147、148、149、150、151、152、154、155、156、157、158、159、160、161、163、 164, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197 97, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228 8, 229, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260 , 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291,292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327 27, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362 2, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​385, 387, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426 , 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460 and 461 compounds. In an embodiment, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73 ,74,75,76,77,81,82,83,90,91,93,94,95,96,97,98,100,101,102,103,104,108,119,121,122,123,124,125,126,127,128,129,130,131,132,133,134,136,137,138,140,141,142,143,144,145,146,147,148,149,150,151,152,154,155,156,157,158,159,160、161、163、164、166、167、168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、188、189、191、192、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、231、232、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、342、343、344、345、346、347、349、350、351、353、354、355、356、357、358、361、364、365、366、367、368、369、370、371、372、374、375、376、377、378、379、381、382、383、384、385、386、387、388、390、391、392、393、395、397、398、399、400、401、402、403、404、405、406、407、408、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、431、432, 433, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 446, 447, 448, 449, 451, 453, 454, 456, 457, 458, 459, 460 and 461 compounds. In other embodiments, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 42, 43, 44, 45, 46, 47, 50, 51, 53, 54, 56, 57, 61, 62, 63, 65, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 81, 82, 90, 91, 93, 94, 95, 96, 97, 98, 100, 101, 102, 103, 108, 119, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 137, 138, 140, 142, 143, 144, 145, 146, 148, 149, 150, 151, 152, 154, 155, 156, 157, 159, 160, 161, 163, 164, 166, 167, 168, 169, 170, 173, 174, 175, 176, 177, 178, 179, 180, 181, 1 82、183、184、185、188、189、191、192、194、195、196、197、198、199、200、202、203、204、205、208、209、210、212、213、215、216、219、220、222、224、225、226、227、228、229、231、234、235、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、 256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、326、327、328、329、331、332、334、335、336、338、339、340、343、344、345、346、349、350、351、353、354、355、356、357、364、366、368、370、371、372、374、375、376、377、381、 382, 383, 384, 385, 387, 390, 392, 397, 398, 399, 400, 401, 403, 404, 405, 406, 408, 414, 416, 418, 420, 422, 423, 424, 426, 427, 428, 429, 431, 435, 437, 440, 441, 442, 443, 444, 446, 447, 448, 449, 451, 457, 458, 459, 460 and 461 compounds. In other embodiments, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 36, 37, 39, 42, 43, 44, 46, 47, 50, 51, 53, 56, 57, 61, 62, 63, 65, 67, 68, 69, 70, 71, 72, 73, 74, 75 9, 70, 72, 73, 74, 75, 76, 81, 82, 93, 94, 95, 96, 97, 98, 100, 101, 102, 103, 119, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 140, 143, 144, 145, 146, 148, 149, 150, 151, 152, 154、155、156、157、159、160、161、164、166、167、168、169、170、173、174、175、176、177、178、179、180、181、182、183、184、185、188、189、191、194、195、196、197、198、199、200、202、203、204、 205, 208, 210, 213, 216, 219, 220, 222, 224, 225, 227, 229, 231, 234, 235, 237, 238, 239, 241, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 256, 257, 258, 260, 261, 262, 264, 265, 266,267, 268, 269, 270, 271, 272, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 294, 295, 296, 297, 298, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 311, 312, 313, 314, 315, 316, 318, 319, 320, 322, 323, 324, 326, 327, 328, 329, 331, 332, 334, 335, 338, 340, 343, 344, 345, 346, 349, 350, 351, 354, 356, 357, 364, 370, 372, 374, 375, 377, 381, 382, ​​383, 384, 385, 387, 390, 392, 397, 398, 405, 406, 408, 418, 420, 422, 423, 424, 426, 427, 428, 429, 435, 440, 441, 443, 444, 446, 447, 448, 449, 451, 457, 458, 459, 460 and 461 compounds. In other embodiments, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 22, 23, 24, 25, 26, 27, 28, 29, 34, 36, 37, 43, 44, 47, 50, 51, 57, 63, 65, 67, 68, 70, 72, 73, 74, 75, 76, 9 3, 94, 96, 97, 98, 100, 101, 102, 103, 119, 121, 123, 124, 125, 126, 127, 128, 130, 131, 132, 133, 140, 144, 145, 146, 148, 149, 150, 151, 152, 154, 155, 156, 159, 160, 161, 166, 167, 169, 170, 173, 174, 175, 178, 179, 181, 182, 183, 184, 185, 188, 189, 191, 195, 196, 197, 198, 199, 200, 202, 204, 205, 208, 219, 220, 222, 227, 231, 23 7, 238, 239, 244, 245, 247, 248, 249, 251, 252, 253, 256, 257, 258, 261, 262, 264, 265, 266, 267, 268, 269, 270, 271, 274, 275, 276, 277, 280, 281, 282, 283, 284, 285,286, 287, 288, 289, 292, 294, 296, 297, 298, 302, 303, 305, 306, 307, 308, 309, 311, 312, 313, 314, 316, 318, 319, 320, 326, 327, 328, 329, 331, 334, 335, 343, 344, 345, 346, 349, 350, 357, 364, 385, 390, 392, 398, 405, 422, 423, 424, 426, 427, 428, 429, 435, 440, 443, 444, 447, 448, 451, 458 and 460 compounds. In other embodiments, the compound is selected from Examples 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 22, 29, 37, 44, 51, 57, 63, 65, 70, 72, 73, 74, 75, 94, 96, 97, 98, 100, 101, 121, 123, 125, 127, 128, 131, 133、140、146、148、149、150、151、152、154、155、156、159、169、170、173、174、175、178、181、184、185、188、189、191、195、197、198、200、202、204、208、219、220、 222、227、231、237、238、239、244、247、248、249、251、252、253、256、258、262、264、265、266、268、269、270、271、277、280、281、282、283、284、285、287、288、289、 297, 302, 305, 307, 308, 311, 314, 316, 318, 319, 320, 328, 329, 331, 334, 335, 343, 346, 349, 350, 385, 392, 398, 405, 426, 428, 429, 435, 443, 447, 451 and 460 compounds. In other embodiments, the compound is selected from Examples 3, 4, 5, 9, 12, 13, 22, 29, 37, 44, 65, 72, 97, 101, 123, 127, 128, 133, 140, 146, 149, 150, 151, 152, 154, 156, 169, 170, 173, 174, 175, 178, 184, 185, 188, 189, 191, 197, 202, 204, 208, 219, 222, 237, 249, 251, 253, 256, 262, 268, 270, 271, 281, 282, 283, 284, 285,Compounds of 287, 288, 289, 307, 318, 343, 428, 435 and 460.

[0198] In an embodiment, the compound is selected from the group consisting of compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, and 68. In an embodiment, the compound is selected from the group consisting of compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 55, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, and 68. In other embodiments, the compound is selected from the compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 54, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, and 68. In other embodiments, the compound is selected from the compounds of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 42, 43, 44, 45, 46, 47, 50, 51, 56, 57, 60, 61, 63, 65, 67, and 68. In other embodiments, the compound is selected from the compounds of Examples 1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13, 19, 20, 22, 24, 25, 26, 27, 28, 29, 34, 36, 37, 42, 43, 44, 46, 47, 50, 51, 57, 65, 67, and 68. In embodiments, the compound is selected from the compounds of Examples 1, 3, 4, 5, 7, 8, 9, 11, 12, 13, 22, 26, 27, 28, 29, 34, 37, 44, 57, and 65. In other embodiments, the compound is selected from the compounds of Examples 3, 4, 5, 9, 11, 12, 22, 29, and 37.

[0199] In an embodiment, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117 7, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148 、149、150、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、167、168、169、170、171、172、173、174、175、176、177、178、179、 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211 11, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242 2, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273,274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​400, 432, and 436 compounds. In an embodiment, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43 ,44,45,46,47,48,49,50,51,52,54,55,56,57,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,81,82,83,89,90,91,92,93,94,95,96,97,98,9 9, 100, 101, 102, 103, 104, 108, 114, 119, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147 , 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182,183、184、185、186、187、188、189、190、191、192、193、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、231、232、233、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、432、433、434、435、436、437、438、439, 440, 441, 442, 443, 444, 447, 451, 452, 453, 454, 456, 457, 458, 459 and 460. In other embodiments, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 50, 51, 54, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 81, 82, 90, 91, 94, 95, 96, 97, 98, 100, 101, 102, 103, 119, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 140, 142, 143, 144, 145, 146, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 166, 167, 168, 169, 170, 172, 173, 174, 175, 176, 177, 178, 179 9, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 208, 210, 211, 212, 213, 214, 215, 216, 217, 219, 220, 221, 222, 224, 225, 227, 228, 229, 231, 232, 233, 234, 235, 237, 238, 239, 240, 241, 242, 243, 244, 245 , 246, 247, 248, 249, 250, 251, 252, 253, 254, 256, 257, 258, 259, 260, 261, 262, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、342、343、 344、345、346、347、349、350、351、353、354、355、356、357、358、359、361、364、365、366、367、368、369、370、371、372、373、374、375、376、377、379、380、381、382、384、 385, 386, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 447, 451, 453, 454, 456, 457, 458, 459 and 460 compounds. In other embodiments, the compound is selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 42, 43, 44, 45, 46, 47, 50, 51, 56, 57, 60, 61, 63, 65, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 81, 82, 90, 91, 94, 95, 96, 97, 98, 100, 101, 102, 103, 104, 105 03, 119, 121, 122, 123, 125, 126, 127, 128, 129, 130, 131, 132, 133, 136, 137, 138, 140, 142, 143, 144, 145, 146, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 159, 160, 161, 162, 164, 166, 167, 168, 169, 170, 173, 174, 175, 176, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187,188, 189, 191, 194, 195, 196, 197, 198, 199, 200, 202, 203, 204, 205, 208, 210, 212, 213, 215, 216, 219, 222, 225, 227, 228, 231, 234, 235, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 256, 257, 258, 259, 260, 261, 262, 265, 2 66, 268, 269, 270, 271, 272, 273, 274, 275, 277, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 300, 301, 302, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 327, 328 8, 329, 330, 331, 332, 333, 334, 335, 336, 338, 339, 340, 342, 343, 344, 345, 346, 349, 350, 351, 353, 354, 355, 356, 357, 358, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 379, 380, 381, 382, ​​384, 385, 386, 388, 389, 390, 391, 392, 393, 394, 395 , 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 447, 451, 453, 454, 457, 458, 459, and 460. In other embodiments, the compound is selected from Examples 1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 13, 15, 17, 19, 20, 22, 24, 25, 26, 27, 28, 29, 34, 36, 37, 42, 43, 44, 46, 47, 50, 51, 57, 65, 67, 68, 69, 70, 72, 75,76, 77, 94, 96, 97, 98, 100, 101, 102, 103, 119, 121, 122, 125, 126, 127, 128, 130, 131, 132, 133, 140, 143, 144, 145, 146, 148, 149, 150, 153, 154, 155, 156, 159, 160, 161, 166, 167, 169, 170, 173, 174, 175, 178, 179, 181, 184, 185, 186, 187, 188, 189 9, 191, 195, 196, 197, 198, 199, 200, 202, 204, 208, 212, 216, 219, 222, 228, 231, 234, 237, 238, 239, 241, 242, 244, 245, 248, 249, 251, 252, 253, 256, 257, 258, 262, 265, 268, 269, 270, 271, 281, 282, 283, 284, 285, 287, 288, 289, 290, 291, 292, 294 , 296, 297, 298, 302, 304, 305, 306, 308, 309, 311, 312, 313, 316, 318, 320, 323, 327, 328, 331, 332, 333, 334, 335, 336, 340, 343, 344, 349, 350, 351, 353, 354, 355, 356, 357, 364, 365, 366, 367, 370, 371, 372, 374, 375, 376, 377, 379, 381, 382, ​​384 , 385, 386, 390, 391, 392, 397, 398, 399, 400, 401, 403, 404, 405, 409, 414, 415, 416, 417, 418, 419, 420, 422, 423, 425, 426, 427, 428, 429, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 447, 451, 453, 454, 457, 458, 459 and 460. In an embodiment, the compound is selected from Examples 1, 3, 4, 5, 7, 8, 9, 11, 12, 13, 15, 17, 22, 26, 27, 28, 29, 34, 37, 44, 57, 65, 70, 72, 75, 76, 96, 97, 98, 101, 102, 121, 122, 125, 126, 127, 128, 131, 132, 133, 140, 144, 146, 149, 150, 154, 155, 156, 166, 167, 170, 173, 174, 178,184、185、186、187、189、195、197、198、199、200、204、212、219、222、231、237、238、244、245、248、249、251、253、256、262、268、270、271、282、283、284、285、289、290、294、297、302、305、308、311、344、349、350、351、356、 357, 364, 365, 366, 367, 370, 371, 372, 375, 377, 381, 382, ​​384, 385, 398, 399, 403, 404, 405, 409, 416, 417, 418, 420, 422, 423, 426, 427, 428, 429, 432, 433, 435, 436, 440, 441, 443, 444, 447, 451, 453, 458, 459 and 460 compounds. In other embodiments, the compound is selected from Examples 3, 4, 5, 9, 11, 12, 15, 17, 22, 29, 37, 75, 97, 101, 121, 125, 127, 128, 131, 133, 146, 150, 154, 156, 166, 170, 173, 174, 178, 186, 187, 189, 197, 198, 199 , 200, 204, 222, 237, 251, 253, 256, 270, 283, 284, 305, 350, 356, 357, 365, 366, 372, 381, 382, ​​385, 398, 405, 418, 426, 427, 428, 429, 432, 435, 436, 443, 447, 451 and 460.

[0200] Pharmaceutical composition

[0201] The present disclosure provides a pharmaceutical composition comprising a compound described herein (eg, a compound of Formula (I) or a pharmaceutically acceptable salt thereof) and at least one pharmaceutically acceptable excipient or carrier.

[0202] In an embodiment, the pharmaceutical composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (IA) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (IB) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (IC) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (ID) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (II) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (III) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (IV) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (V) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (VI) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (VI-A) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (VII) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (VII-A) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (VIII) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (VIII-A) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (IX) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (IX-A) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (X) or a pharmaceutically acceptable salt thereof. In an embodiment, the pharmaceutical composition comprises a compound of formula (XA) or a pharmaceutically acceptable salt thereof.

[0203] The pharmaceutical compositions of the present disclosure may be formulated for administration in solid or liquid form, for example using conventional carriers or excipients. Using techniques known in the art, the compositions may be suitable, for example, for oral administration (e.g., as solutions, suspensions, tablets or capsules), parenteral administration (e.g., as solutions, dispersions, suspensions or emulsions, or as dry powders for reconstitution) or topical application (e.g., as creams, ointments, patches or sprays for application to the skin).

[0204] Medical Uses

[0205] The compounds of the present disclosure act as inhibitors of ERK5, which makes them useful in the treatment of ERK5-related disorders and conditions. In particular, the compounds of the present disclosure can be used to treat cancer.

[0206] From this aspect, the present disclosure provides a method of treatment, comprising administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) to a subject in need thereof. In a related aspect, the present disclosure provides the use of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament. In another related aspect, the present disclosure provides a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) for use in therapy.

[0207] The compounds of the present disclosure can be used to treat or prevent: diseases or deleterious conditions in which ERK5 or its variants or mutants are known to play a role; diseases or disorders associated with increased expression of MAPK7 (i.e., the ERK5 gene) and / or increased ERK5 activity; and diseases or disorders in which inhibition or antagonism of ERK5 activity is beneficial.

[0208] In one aspect, the present disclosure provides a method for treating or preventing a disease or disorder mediated by ERK5 or a disease or disorder involving ERK5 in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the present disclosure provides the use of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for treating or preventing a disease or disorder mediated by ERK5 or a disease or disorder involving ERK5. In another related aspect, the present disclosure provides a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) for treating or preventing a disease or disorder mediated by ERK5 or a disease or disorder involving ERK5.

[0209] In another aspect, the present disclosure provides a method for treating or preventing a disease or disorder associated with ERK5 (e.g., cancer) in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the present disclosure provides the use of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for treating or preventing a disease or disorder associated with ERK5 (e.g., cancer). In another related aspect, the present disclosure provides a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) for treating or preventing a disease or disorder associated with ERK5 (e.g., cancer).

[0210] In another aspect, the present disclosure provides a method for treating or preventing cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof). In a related aspect, the present disclosure provides the use of a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for treating or preventing cancer. In another related aspect, the present disclosure provides a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof) for treating or preventing cancer.

[0211] In embodiments, the compound reduces angiogenesis, reduces or prevents metastasis, reduces inflammation, blocks tumorigenesis (e.g., partially or completely), reduces growth suppression escape, reduces or inhibits the growth of cancerous or precancerous cells, inhibits the proliferation of cancerous or precancerous cells, and / or reduces the survival of cancerous or precancerous cells.

[0212] In embodiments, cancer is characterized by increased expression of MAPK7 (i.e., ERK5 gene) and / or increased ERK5 activity. In embodiments, cancer has elevated ERK5 activity. In embodiments, cancer overexpresses ERK5. In embodiments, cancer is characterized by MAPK7 genomic amplification and / or constitutively activated ERK5 signaling. In embodiments, cancer has genomic amplified ERK5. In embodiments, cancer has constitutively activated ERK5 signaling.

[0213] In embodiments, the cancer is a solid tumor (e.g., melanoma, carcinoma, or blastoma). In other embodiments, the cancer is a leukemia (e.g., chronic lymphocytic leukemia, CLL; acute myeloid leukemia, AML; or chronic myeloid leukemia, CML).

[0214] In embodiments, the cancer is a primary tumor. In other embodiments, the cancer is a secondary tumor (e.g., a metastatic tumor).

[0215] In embodiments, the cancer is selected from breast cancer (e.g., ductal breast cancer or breast adenocarcinoma), liver cancer, kidney cancer (e.g., hepatocellular carcinoma), prostate cancer, colorectal cancer (CRC), lung cancer (e.g., non-small cell lung cancer, NSCLC; lung adenocarcinoma; or lung squamous cell carcinoma), pancreatic cancer (e.g., adenocarcinoma), ovarian cancer, brain cancer (e.g., glioblastoma), cervical cancer (e.g., adenocarcinoma), gastric cancer, skin cancer, bile duct cancer (e.g., cholangiocarcinoma), nervous system cancer (e.g., neuroblastoma), and melanoma.

[0216] In embodiments, the cancer is selected from leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute granulocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelo-monocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin's disease or non-Hodgkin's disease), Waldenstrom's macroglobulinemia, and multiple myeloma.

[0217] In embodiments, the cancer is selected from leukemia (eg, chronic myeloid leukemia), breast cancer, multiple myeloma, colon cancer, renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma, and hepatocellular carcinoma.

[0218] In another aspect, the present disclosure provides a method of inhibiting ERK5 activity, the method comprising contacting ERK5 (e.g., a cell comprising ERK5) with a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof). In embodiments, the method is an in vitro or ex vivo method. In other embodiments, the method is an in vivo method. In a related aspect, the present disclosure provides an in vitro method of inhibiting ERK5 activity in a cell, the method comprising contacting the cell with a compound of the present disclosure (e.g., a compound of formula (I) or a pharmaceutically acceptable salt thereof).

[0219] The compounds of the present disclosure (eg, compounds of Formula (I)) and pharmaceutically acceptable salts thereof may be administered as pharmaceutical compositions, which may optionally contain one or more pharmaceutically acceptable excipients.

[0220] It should be understood that the methods and treatments of various aspects of the present disclosure can be achieved by administering to a subject an effective amount of a compound of the present disclosure (e.g., a compound of Formula (I) or a pharmaceutically acceptable salt thereof) in the form of a pharmaceutical composition, which may optionally contain one or more pharmaceutically acceptable excipients, as described herein.

[0221] The compounds of the present disclosure can be used alone (eg, as a monotherapy) or in combination with one or more cancer therapies.

[0222] Having generally been described herein, the following non-limiting examples are provided to further illustrate the disclosure. Example

[0223] General synthetic scheme

[0224] The following scheme, Scheme 1A, illustrates an exemplary manner to prepare compounds according to the present disclosure and examples: According to Scheme 1A (where R 1 , L 1 , R 2 , L 2 , R 3 , R 4 , R 5 and n may be, for example, as described above), in step 1, compound 1C may be obtained by Suzuki coupling between compound 1A (wherein X may be I, Br or Cl) and compound 1B in a mixture of dioxane and water and in the presence of a base (such as potassium carbonate) using, for example, a catalyst (such as [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with DCM) by heating the solvent to reflux. In step 2, for example, compound 1C may be reduced to compound 1D by, for example, heating at 40° C. under a pressure of about 5 bar of hydrogen (H 2 ) pressure in the presence of a catalyst such as Pd / C. Then, in step 3, for example, compound 1D can be converted to compound 1F by adding it to a premixed solution of carboxylic acid (compound 1E) and CDI in acetonitrile, followed by heating to reflux. Alternatively, compound 1D can be coupled with compound 1E using conditions known to those skilled in the art, such as EDC in a solvent like DMF in the presence of a base such as pyridine, followed by heating with AcOH up to 80° C., to provide compound 1F. In step 4, compound 1F can be converted to compound 1G by treatment with an acid such as neat TFA or a solution of HCl in dioxane in a solvent such as MeOH. In step 5, compound 1I (wherein E is -C(O)-) can be obtained by peptide coupling between compound 1G and compound 1H using conditions known to those skilled in the art such as EDC in the presence of 4-DMAP and DIEA in a solvent such as DMF or HATU in the presence of DIEA in a solvent such as DMF. Compound 1I (wherein E is -S(O)-)2 -) can be obtained by treating compound 1G with compound 1H' using conditions known to those skilled in the art, for example, treatment with a base such as triethylamine in a solvent like DCM.

[0225] An alternative way to convert compound 1D to compound 1I is illustrated in the following scheme, Scheme 1B:

[0226] According to Scheme 1B (where R 1 , L 1 , R 2 , L 2 , R 3 , R 4 , R 5 and n may be as described above), in step 1, for example, compound 1J may be obtained by treating compound 1D with an acid (such as TFA) in a solvent (such as DCM), followed by peptide coupling with compound 1H using conditions known to those skilled in the art (such as HATU in a solvent (such as DMF) in the presence of a base (such as DIEA), or reacting with compound 1H' and a base (such as triethylamine) in a solvent (such as DCM). Then, in step 2, compound 1J may be converted to compound 1I (wherein E is -C(O)- or -S(O)) by the following method: 2 -): coupling with compound IE using conditions such as, for example, CDI in acetonitrile followed by heating to reflux.

[0227] Compounds wherein E is -O- can be synthesized by analogy with the methods shown above (e.g., using a modified version of Scheme 1A). For example, an analog of compound 1G (with a carbon atom in place of the piperidine nitrogen and carrying a protected hydroxyl group) (hereinafter compound 1G') can be deprotected and coupled to a moiety containing R by alkylation (e.g., using a Williamson reaction to give an alkyl ether) or a Mitsunobu reaction (e.g., to give an aryl or heteroaryl ether). 2 This is illustrated in the following Scheme 1C:

[0228] Experimental techniques

[0229] At 400 and 500MHz 1 H NMR spectra were performed on Bruker Avance DRX-400 and Bruker Avance DPX-500 spectrometers in the solvent dimethyl sulfoxide-d 6 (DMSO-d 6) The chemical shift (δ, in ppm) is referenced to 2.5 ppm at the cited temperature. The coupling constant (J) is given in Hertz.

[0230] For the intermediates in the following synthetic procedures, liquid chromatography / mass spectrometry (LC / MS) was obtained on a UPLC Acquity Waters instrument, a Sedere light scattering detector, and a SQD Waters mass spectrometer, using UV detection DAD 210 <l< 400 nm and a column Acquity UPLC CSH C18 1.7 μm, size 2.1 x 30 mm, mobile phase H 2 O + 0.0% HCO 2 H / CH 3 CN + 0.0% HCO 2 H.

[0231] For the compounds prepared as the final products of the following synthetic methods (i.e., for the compounds of Examples 1 - 461), LC / MS was obtained as specified by Method 1, Method 2, or Method 3.

[0232] Method 1

[0233] Liquid chromatography / mass spectrometry (LC / MS) was obtained on a Waters ACQUITY UPLC instrument with a Waters SQD2 using positive and negative electrospray ionization (ES+ / -) under the following conditions:

[0234] Method 2

[0235] Liquid chromatography / mass spectrometry (LC / MS) was obtained on a Waters ACQUITY UPLC instrument with a Waters SQD2 using positive and negative electrospray ionization (ES+ / -) under the following conditions:

[0236] Method 3

[0237] Liquid chromatography / mass spectrometry (LC / MS) was obtained on a Waters ACQUITY UPLC instrument with a Waters SQD2 using positive and negative electrospray ionization (ES+ / -) under the following conditions:

[0238] Unless otherwise stated, all synthetic reactions were carried out under an inert atmosphere. In the following examples, when the source of the starting product is not specified, it should be understood that the product is a known compound (e.g., a commercially available compound from a supplier such as Sigma - Aldrich).

[0239] Separation of isomers (eg, chiral separation) of the compounds was performed by one of the following methods as specified in the synthetic methods below.

[0240] Method CS1

[0241] The corresponding mixture (eg, 0.19 mmol thereof) was separated using a chiralpak IC column (20 μm, 100 x 230 mm), eluted with (n-heptane 30%, EtOH 70%) + 0.1% TEA (flow rate 400 mL / min, UV detection at 265 nm).

[0242] Method CS2

[0243] The corresponding mixture (eg, 0.30 mmol thereof) was separated using a chiralpak AD column (20 μm, 350 x 76.5 mm), eluted with (n-heptane 80%, EtOH 20%) + 0.1% TEA (flow rate 400 mL / min, UV detection at 265 nm).

[0244] Method CS3

[0245] The corresponding mixture (eg, 0.08 mmol thereof) was separated using an I Cellulose 5 column (5 μm, 250×30 mm), eluted with (n-heptane 40%, EtOH 60%) + 0.1% TEA (flow rate 1 mL / min, UV detection at 265 nm).

[0246] Method CS4

[0247] The corresponding mixture (eg, 0.1 mmol thereof) was separated using Chiralcel OD-H column (5 μm, 250×30 mm), eluting with (n-heptane 85%, EtOH 15%) + 0.1% TEA (flow rate 40 mL / min, UV detection at 265 nm).

[0248] Method CS5

[0249] The corresponding mixture (eg, 0.35 mmol thereof) was separated using a Phenomenex Cellulose-4 column (20 μm, 350 x 76.5 mm) eluted with (n-heptane 50% TEA 0.1%, EtOH 50% TEA 0.1%) (flow rate 24 L / h, UV detection at 265 nm).

[0250] Method CS6

[0251] The corresponding mixture (eg, 0.08 mmol thereof) was separated using an i-amylose-3 column (5 μm, 250×30 mm) and eluted with (n-heptane 80%, EtOH 20%) + TEA 0.1% (flow rate 40 mL / min, UV detection at 265 nm).

[0252] Method CS7

[0253] The corresponding mixture (eg, 0.26 mmol thereof) was separated using a Chiralpak AS column (10 μm, 250 x 4.6 mm), eluted with (MeOH 40%, CO2 60%) + TEA 0.1% (flow rate 120 mL / min, UV detection at 254 nm).

[0254] Method CS8

[0255] The corresponding mixture (eg, 0.09 mmol thereof) was separated using a Whelk 01SS column (10 μm, 250 x 4.6 mm) eluted with (n-heptane 80% TEA 0.1%, EtOH 20% TEA 0.1%) (flow rate 1 mL / min, UV detection at 265 nm).

[0256] Method CS9

[0257] The corresponding mixture (e.g., 0.18 mmol) was separated using a Chiralpak IJ column (5 μm, 250 x 30 mm) and washed with (MeOH 20%, CO 2 80%) (flow rate 200 mL / min, UV detection at 265 nm).

[0258] Method CS10

[0259] The corresponding mixture (eg, 0.11 mmol thereof) was separated using a Cellulose 4 column (5 μm, 250 x 4.6 mm) eluted with (n-heptane 40%, EtOH 60%) + 0.1% TEA (flow rate 1 mL / min, UV detection at 265 nm).

[0260] Method CS11

[0261] The corresponding mixture (eg, 0.07 mmol thereof) was separated using Chiralpak OZ-H column (5 μm, 250×30 mm), eluted with (n-heptane 80%, EtOH 20%) + 0.1% TEA (flow rate 40 mL / min, UV detection at 265 nm).

[0262] Method CS12

[0263] The corresponding mixture (eg, 0.18 mmol thereof) was separated using a Chiralpak AY column (20 μm, 230×100 mm), eluted with (n-heptane 80%, EtOH 20%) + 0.1% TEA (flow rate 400 mL / min, UV detection at 265 nm).

[0264] Method CS13

[0265] The corresponding mixture (eg, 0.28 mmol thereof) was separated using Chiralpak OZ column (20 μm, 250 x 4.6 mm), eluted with (n-heptane 20%, EtOH 80%) + 0.1% TEA (flow rate 1 mL / min, UV detection at 265 nm).

[0266] Method CS14

[0267] The corresponding mixture (eg, 0.075 mmol thereof) was separated using a Chiralpak IG column (5 μm, 250×30 mm), eluted with (n-heptane 85%, ethanol 15%) + 0.1% TEA (flow rate 40 mL / min, UV detection at 265 nm).

[0268] Method CS15

[0269] The corresponding mixture (e.g., 0.10 mmol thereof) was separated using a chiralpak AD column (20 μm, 50 x 300 mm) and the mixture was purified by (CO 2 (SFC) 85%, MeOH 15%) + 0.1% TEA elution (flow rate 200 mL / min, UV detection at 265 nm).

[0270] Method CS16

[0271] The corresponding mixture (e.g., 0.16 mmol) was separated using an XSELECT CSH prep C18 column (5 μm, 50 x 250 mm) and eluted with (H 2 The mixture was eluted with 0.1% HCOOH, MeCN (flow rate 80 mL / min, UV detection at 265 nm).

[0272] Method CS17

[0273] The corresponding mixture (eg, 0.25 mmol thereof) was separated using Chiracel OD-I column (20 μm, 76.5 x 350 mm), eluting with (n-heptane 70 / EtOH 30) + 0.1% TEA (flow rate 400 mL / min, UV detection at 280 nm).

[0274] Method CS18

[0275] The corresponding mixture (eg, 0.18 mmol thereof) was separated using a Chiralpak IH column (5 μm, 250×30 mm), eluted with (n-heptane 82%, ethanol 18%) + 0.1% TEA (flow rate 40 mL / min, UV detection at 265 nm).

[0276] Method CS19

[0277] The corresponding mixture (eg, 0.36 mmol thereof) was separated using a Phenomenex lux amylose-1 column (5 μm, 250 x 30 mm), eluted with (n-heptane 80%, EtOH 20%) + TEA 0.1% (flow rate 45 mL / min, UV detection at 265 nm).

[0278] Method CS20

[0279] The corresponding mixture (eg, 0.18 mmol thereof) was separated using a Chiralpak IF column (5 μm, 250×30 mm), eluted with (n-heptane 80%, ethanol 20%) + 0.1% TEA (flow rate 1 mL / min, UV detection at 265 nm).

[0280] Method CS21

[0281] The corresponding mixture was separated using a Chiralpak AS-H column (5 μm, 20 x 250 mm) and the mixture was purified by CO 2 / 30% (MeOH+0.1% TEA) elution, flow rate 50 mL / min, UV detection at 254 nm, back pressure regulator 100 bar, T=40°C.

[0282] Examples 1 to 461 - Compounds

[0283] Table 1 below lists the compounds synthesized in the following Synthesis Examples.

[0284] Table 1:

[0285] Examples 1 and 2: [2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone Isomers 1 and 2

[0286] Step 1: tert-Butyl 4-(2-amino-3-nitro-4-pyridinyl)-3,6-dihydro-2H-pyridine-1-carboxylate

[0287] In a 2-liter three-necked flask equipped with a reflux condenser, a thermometer and a bubbler, 4-chloro-3-nitro-pyridin-2-amine (20 g, 115.2 mmol), K3 PO 4 The mixture of 1,4-dioxane (1000mL) and water (112mL) was purged with argon for 15 minutes. Then, 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (4.71g, 5.76mmol) was added, and the resulting reaction mixture was stirred at 90°C for 12 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and 350mL of AcOEt, 350mL of water were added. The organic phase was separated, and the aqueous phase was extracted three times with AcOEt (3x 350mL). The combined organic layer was then washed twice with water (2x 350mL), then washed with brine (350mL), dried over magnesium sulfate and concentrated in vacuo. The resulting crude residue (85 g of brown oil) was purified by flash chromatography (SiO 2 600 g, eluted with heptane 75 / AcOEt 25 at 100 mL / min) to give 16.02 g (43%) of tert-butyl 4-(2-amino-3-nitro-4-pyridinyl)-3,6-dihydro-2H-pyridine-1-carboxylate as a yellow solid. LC / MS (m / z, M+H): 321

[0288] Step 2: tert-Butyl 4-(2,3-diamino-4-pyridinyl)piperidine-1-carboxylate

[0289] 4-(2-amino-3-nitro-4-pyridinyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (16 g, 49.95 mmol) and 10% Pd / C (2.66 g, 2.5 mmol) in MeOH (637 mL) were placed in a high pressure reactor. This mixture was then hydrogenated with 5 bar of hydrogen at 40° C. for 48 hours. The reaction mixture was then cooled to room temperature and The filtrate was concentrated in vacuo to give 14.92 g of a brown wax, which was then washed with 10 mL of Et 2 O+3mL of iPr 2 The resulting solid was filtered to give 10.95 g (75%) of tert-butyl 4-(2,3-diamino-4-pyridinyl)piperidine-1-carboxylate as a brown solid. LC / MS (m / z, M+H): 293.

[0290] Step 3: (rac)-tert-butyl 4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carboxylate

[0291] Under argon atmosphere, at room temperature, CDI (166mg, 1.02mmol) was added to a solution of 2-tetrahydrofuran-3-yl acetic acid (111mg, 0.85mmol) in acetonitrile (9mL). The resulting mixture was stirred at room temperature for 20 minutes, and 4-(2,3-diamino-4-pyridyl) piperidine-1-tert-butyl formate (250mg, 0.85mmol) was added. The resulting mixture was then refluxed for 36 hours under argon atmosphere. The reaction mixture was then concentrated in a vacuum, diluted with AcOEt (50mL), transferred to a separating funnel, washed with water (50mL) and washed with saturated sodium chloride aqueous solution (50mL). The organic layer was dried over sodium sulfate, filtered and concentrated in a vacuum. The resulting residue (black oil) was purified by flash chromatography (SiO 2 12 g, washed with DCM 93 / MeOH 7 / NH 4 OH 0.7) to give a brown solid which was then purified by iPr 2 O, filtered and dried under vacuum to give 143 mg (43%) of tert-butyl 4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carboxylate as a light brown solid. LC / MS (m / z, M+H): 387.

[0292] Step 4: (rac)-7-(4-piperidinyl)-2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridine dihydrochloride

[0293] To a solution of tert-butyl 4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]piperidine-1-carboxylate (140 mg, 0.36 mmol) in MeOH (2 mL) was added 4N HCl solution in dioxane (0.91 mL, 3.62 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated and dried under vacuum to give 137 mg (100%) of (racemic)-7-(4-piperidinyl)-2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridine dihydrochloride as a light brown solid. LC / MS (m / z, M+H): 360 (free base).

[0294] Step 5: (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone

[0295] To a solution of (racemic)-7-(4-piperidinyl)-2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridine dihydrochloride (130 mg, 0.36 mmol) in DMF (2.4 mL) was added DIPEA (0.32 mL, 1.81 mmol) under argon atmosphere at room temperature. After the starting material was dissolved, 2-amino-4-(trifluoromethoxy)benzoic acid (88 mg, 0.4 mmol) was added, followed by HATU (165 mg, 0.43 mmol). The resulting mixture was then stirred at room temperature for 2 hours. The reaction mixture was diluted with AcOEt (40 mL), transferred to a separatory funnel, and washed with saturated NaHCO 3 The organic layer was then dried over sodium sulfate, filtered and concentrated in vacuo. The resulting residue (brown oil) was purified by flash chromatography (SiO 2 12 g, washed with DCM 93 / MeOH 7 / NH 4 OH 0.7 (eluted) to give 106 mg (59%) of (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone as a light yellow solid. LC / MS (m / z, M+H): 490.

[0296] Chiral separation of (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone (83 mg, 0.17 mmol) was performed using a chiralpak AY column (20 μm, 100 x 230 mm) eluted with (n-heptane 80%, EtOH 15%, MeOH 5%) + 0.1% TEA (flow rate 40 mL / min, UV detection at 280 nm) to give 37 mg (44%) of the first eluting isomer 1 (Example 1) as a white solid and 40 mg (48%) of isomer 2 (Example 2).

[0297] Isomer 1 (Example 1) : LC / MS (m / z, M+H, method 2): calculated value 490, found value 490.3; 1H NMR (400 MHz, DMSO-d6, 30°C, mixture of conformers 70 / 30) δ ppm 1.54-1.70 (m, 1H), 1.70-1.95 (m, 4H), 1.95-2.09 (m, 1H), 2.69-2.81 (m, 1H), 2.84-3.22 (m, 2H), 2.89 (br d, J = 7 Hz, 2H), 3.18-3.40 (m partially hidden, 1H), 3.39-3.53 (m, 2H), 3.66 (q, J = 8 Hz, 1H), 3.74-3.85 (m, 2H), 3.89-4.65 (m, 1H), 5.58 (br s, 2H), 6.49 (br d, J = 8 Hz, 1H), 6.66 (br d,J=1Hz,1H),7.05(d,J=5Hz,1H),7.15(br d,J=8Hz,1H),8.14(br d,J=5Hz,0.7H),8.18-8.35(m,0.3H),12.49(br s,0.3H),12.80(br s,0.7H).

[0298] Isomer 2 (Example 2) : LC / MS (m / z, M+H, method 2): calculated value 490, found value 490.3; 1HNMR (400 MHz, DMSO-d6, 30°C, mixture of conformers 70 / 30) δppm 1.57-1.69 (m, 1H), 1.70-1.94 (m, 4H), 1.95-2.09 (m, 1H), 2.69-2.81 (m, 1H), 2.85-2.96 (m, 2H), 2.95-3.40 (m partially hidden, 3H), 3.39-3.52 (m, 2H), 3.58-3.71 (m, 1H), 3.73-3.87 (m, 2H), 5.58 (s, 1.4H), 5.61 (s, 0.6H), 6.49 (br d,J=8Hz,1H),6.66(br s,1H),7.02-7.08(m,1H),7.12-7.22(m,1H),8.14(d,J=5Hz,0.7H),8.23(d,J=5Hz,0.3H),12.47(s,0.3H),12.78(br s,0.7H).

[0299] Examples 3 and 4: [2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone Isomers 1 and 2

[0300] Step 1: (rac)-tert-butyl 4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carboxylate

[0301] Step 1 of Examples 3 and 4 was prepared according to a procedure similar to that of Step 3 of Examples 1 and 2 from tert-butyl 4-(2,3-diamino-4-pyridinyl)piperidine-1-carboxylate (250 mg, 0.86 mmol) and tetrahydrofuran-3-carboxylic acid (99 mg, 0.85 mmol) in acetonitrile (8.6 mL) to give 144 mg (45%) of tert-butyl (rac)-4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carboxylate as a light brown solid. LC / MS (m / z, M+H): 373.

[0302] Step 2: (rac)-7-(4-piperidinyl)-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridine dihydrochloride

[0303] Step 2 of Examples 3 and 4 was prepared from (rac)-tert-butyl 4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carboxylate (141 mg, 0.38 mmol) according to a procedure similar to that of Step 4 of Examples 1 and 2 to give 130 mg (100%) of (rac)-7-(4-piperidinyl)-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridine dihydrochloride as a light brown solid. LC / MS (m / z, M+H): 273.

[0304] Step 3: (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone

[0305] Step 3 of Examples 3 and 4 was prepared from (rac)-7-(4-piperidinyl)-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridine dihydrochloride (130 mg, 0.38 mmol) according to a procedure similar to that of Step 5 of Examples 1 and 2 to give 118 mg (64%) of (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone as a light yellow solid. LC / MS (m / z, M+H): 476.

[0306] Chiral separation of (rac)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone (93 mg, 0.19 mmol) was performed using a chiralpak AY column (20 μm, 100 x 230 mm) eluted with (n-heptane 70%, EtOH 25%, MeOH 5%) + 0.1% TEA (flow rate 40 mL / min, UV detection at 265 nm) to give 42 mg (45%) of the first eluting isomer 1 (Example 3) as a white solid and 48 mg (52%) of isomer 2 (Example 4).

[0307] Isomer 1 (Example 3) : LC / MS (m / z, M+H, method 2): calculated value 476, found value 476.1; 1 HNMR(400MHz,DMSO-d6,100℃)δppm 1.82-1.99(m,4H),2.34(q,J=7Hz,2H),3.04-3.17(m,2H),3.35-3.49(m,1H),3.67( quin,J=8Hz,1H),3.83(q,J=7Hz,1H),3.89-4.01(m,2H),4.07-4.12(m,1H),4.16(br d,J=13Hz,2H),5.34(s,2H),6.48(br dd,J=8,1Hz,1H),6.68(brd,J=1Hz,1H),7.01(d,J=5Hz,1H),7.14(d,J=9Hz,1H),8.15(d,J=5Hz,1H),11.88-12.82(m,1H)

[0308] Isomer 2 (Example 4) : LC / MS (m / z, M+H, method 2): calculated value 476, found value 476.1; 1HNMR(400MHz,DMSO-d6,100℃)δppm 1.82-1.99(m,4H),2.34(q,J=7Hz,2H),3.04-3.17(m,2H),3.35-3.49(m,1H),3.67( quin,J=8Hz,1H),3.83(q,J=7Hz,1H),3.89-4.01(m,2H),4.07-4.12(m,1H),4.16(br d,J=13Hz,2H),5.34(s,2H),6.48(br dd,J=8,1Hz,1H),6.68(brd,J=1Hz,1H),7.01(d,J=5Hz,1H),7.14(d,J=9Hz,1H),8.15(d,J=5Hz,1H),11.88-12.82(m,1H)

[0309] Example 5: [2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone

[0310] Step 1: tert-Butyl 4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carboxylate

[0311] CDI (66 mg, 0.41 mmol) was added to a solution of tetrahydropyran-4-carboxylic acid (44 mg, 0.34 mmol) in acetonitrile (3.4 mL) at room temperature, and the reaction mixture was stirred at room temperature for one hour. Then tert-butyl 4-(2,3-diamino-4-pyridyl)piperidine-1-carboxylate (100 mg, 0.34 mmol) was added, and the resulting reaction mixture was refluxed for 36 hours. The reaction mixture was cooled to room temperature. The formed precipitate was filtered, washed with acetonitrile and dried under vacuum to obtain 76 mg (57%) of tert-butyl 4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridine-7-yl)piperidine-1-carboxylate as a light brown solid. LC / MS(m / z,M+H):387

[0312] Step 2: [2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone

[0313] To a solution of 4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridine-7-yl)piperidine-1-carboxylic acid tert-butyl ester (69mg, 0.18mmol) in DCM (1.7mL) was added TFA (0.23mL, 2.87mmol) at room temperature under an argon atmosphere, and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was then concentrated to dryness in a vacuum. The resulting residue was then diluted with DMF (1.2mL), and under an argon atmosphere, DIEA (0.37mL, 2.14mmol) was added, followed by addition of HATU (68mg, 0.18mmol) in batches after 5 minutes. The resulting mixture was then stirred at room temperature for 3.5 hours. The reaction mixture was then diluted with water (15mL) and 1N NaOH aqueous solution (15mL), transferred to a separatory funnel, and extracted three times with AcOEt. The organic layers were combined, washed with a saturated sodium chloride aqueous solution, dried over sodium sulfate and concentrated in a vacuum. The resulting residue was suspended in minimal DCM, 3 drops of MeOH were added to dissolve, then pentane was added stepwise until a white precipitate appeared, which was filtered, washed with pentane and dried under vacuum to give 65 mg (74%) of [2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone as a light yellow solid. LC / MS (m / z, M+H, Method 2): Calculated 490, found 490.2; 1 H NMR (400MHz, DMSO-d6, 101℃) δppm1.75-2.02(m,8H),3.00-3.23(m,3H),3.31-3.47(m,1H),3.44-3.56(m,2H),3.95(dt,J=11,3Hz,2H),4.17(br d,J=13Hz,2H),5.33(s,2H),6.48(dd,J=8,1Hz,1H),6.68(d,J=1Hz,1H),7.00(d,J=5Hz,1H),7.15(d,J=8Hz,1H),8.14(br d,J=5Hz,1H),12-12,6(m,1H).

[0314] Example 6: [4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone

[0315] Step 1: [4-(2,3-Diamino-4-pyridinyl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone

[0316] Under argon atmosphere, at 0 ° C, TFA (4.7 mL, 62 mmol) was added dropwise to a solution of tert-butyl 4-(2,3-diamino-4-pyridyl)piperidine-1-formate (1.8 g, 6.2 mmol) in DCM (10 mL). The reaction mixture was then stirred at room temperature for 3.5 hours. The reaction mixture was then concentrated to dryness, and the resulting residue was diluted with DMF (20 mL) under an argon atmosphere, and DIEA (11 mL, 62 mmol) was added at 0 ° C. The resulting mixture was stirred for 10 minutes, and 4-(trifluoromethoxy)benzoic acid (1.3 g, 62 mmol) was added, followed by addition of HATU (2.3 g, 6.2 mmol) in batches. The reaction mixture was stirred at room temperature for 12 hours, then diluted with 80 mL of water, transferred to a separatory funnel, extracted three times with AcOEt (3x30 mL). The combined organic layer was washed with 1N NaOH solution, washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The resulting residue was purified by flash chromatography (SiO 2 The mixture was stirred for 2 hours at room temperature for 1 hour. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours. The mixture was stirred for 2 hours at room temperature for 3 hours.

[0317] Step 2: tert-Butyl 4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidine-1-carboxylate

[0318] Step 2 of Example 6 was prepared according to a procedure similar to that of Step 1 of Example 5 from [4-(2,3-diamino-4-pyridinyl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone (150 mg, 0.39 mmol) and 1-tert-butoxycarbonylpiperidine-4-carboxylic acid (92 mg, 0.39 mmol) to give 145 mg (64%) of tert-butyl 4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidine-1-carboxylate as a white solid. LC / MS (m / z, M+H): 574.

[0319] Step 3: [4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone

[0320] To a solution of tert-butyl 4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidine-1-carboxylate (139 mg, 0.24 mmol) in DCM (0.5 mL) was added TFA (0.22 mL, 2.87 mmol) under an argon atmosphere at room temperature, and the resulting reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then concentrated in vacuo, diluted with AcOEt, and washed with 1N NaOH solution. The aqueous phase was extracted twice with AcOEt. The combined organic layers were then washed with brine, dried over sodium sulfate, filtered and concentrated. The resulting residue was then purified by reverse phase HPLC with a 5 μm CSH column (250 x 50 mm) (94% A(H 2 0+0.1% formic acid) and 6% B (acetonitrile+0.1% formic acid), and then gradually eluted to 26% B at t=25 minutes (flow rate: 150 mL / min; room temperature) to obtain 12 mg of [4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone as a white solid. LC / MS (m / z, M+H, method 1): calculated value 474, found value 474.2; 1 HNMR (300 MHz, DMSO-d6, 120°C) δ ppm 1.68-2.04 (m, 8H), 2.58-2.74 (m, 2H), 2.85-3.03 (m partially hidden, 1H), 3.03-3.21 (m, 4H), 3.36-3.50 (m, 1H), 4.16 (br d, J = 12 Hz, 2H), 6.99 (d, J = 5 Hz, 1H), 7.37 (br d, J = 9 Hz, 2H), 7.56 (d, J = 9 Hz, 2H), 8.14 (d, J = 5 Hz, 1H).

[0321] Example 7: (trans)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone

[0322] Step 1: (trans)-4-acetoxycyclohexanecarboxylic acid

[0323] At 5 ° C, under an argon atmosphere, acetic anhydride (2.5 mL, 26 mmol) was added dropwise to a solution of (trans)-4-hydroxycyclohexanecarboxylic acid (500 mg, 3.29 mmol) in pyridine (5 mL). After 10 minutes, the reaction mixture was allowed to warm to room temperature. After one hour, the reaction mixture was poured onto crushed ice and acidified to pH = 1 with HCl. The entire mixture was transferred to a separatory funnel and extracted twice with AcOEt. The combined organic layers were then washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo to give 613 mg (100%) of (trans)-4-acetoxycyclohexanecarboxylic acid as a white solid.

[0324] Step 2: (trans)-[4-[[3-amino-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-2-pyridinyl]carbamoyl]cyclohexyl]acetate

[0325] Step 2 of Example 7 was prepared according to a procedure similar to that of Step 1 of Example 5 from (trans)-[4-(2,3-diamino-4-pyridinyl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone (100 mg, 0.26 mmol) and 4-acetoxycyclohexanecarboxylic acid (52 mg, 0.28 mmol) to give 65 mg (47%) of (trans)-[4-[[3-amino-4-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-2-pyridinyl]carbamoyl]cyclohexyl] acetate as a white solid. LC / MS (m / z, M+H): 531

[0326] Step 3: (trans)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone

[0327] A solution of acetic acid (trans) -4- [[3- amino -4- [1- [4- (trifluoromethoxy) benzoyl] -4- piperidinyl] -2- pyridinyl] carbamoyl] cyclohexyl] ester (62mg, 0.12mmol) in a mixture of THF 0.5mL / MeOH 0.5mL / (1N NaOH aqueous solution) 0.5mL was stirred at room temperature for 12 hours. After 12 hours, the reaction mixture was concentrated in a vacuum, diluted with water, transferred to a separatory funnel and extracted twice with AcOEt. The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in a vacuum. The resulting residue was then heated to 40 ℃ and dried over 30 ℃ for 12 hours. The resulting residue was then heated to 40 ℃ and dried over 30 ℃ for 12 hours. The resulting residue was then heated to 40 ℃ and dried over 30 ℃ for 12 hours. The resulting residue was then heated to 40 ℃ and dried over 30 ℃ for 12 hours. 2O, filtered and dried under vacuum to give 46 mg (81%) of (trans)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trif...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein: R 1 is selected from -H, -(C1-C6)alkyl, -(C3-C7)cycloalkyl, -(C4-C8)cycloalkenyl, -(C6-C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A independently selected from halo, -OH, -NHR', -CN, oxo, -SO2CH3, -(C1-C3)alkyl, -O(C1-C3)alkyl, -C(O)R", -C(O)NHR', -NHC(O)R", -(C3-C6)cycloalkyl, 3 to 6 membered heterocycloalkyl, phenyl and pyridyl, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl and phenyl is optionally substituted with one or more groups independently selected from halo, -OH, -NH2 and -CN, and / or two of the R A are capable of forming, together with the atom or atoms to which they are attached, a (C3-C6)cycloalkyl or a 3- to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H, methyl and phenyl, and wherein each R" is independently selected from -OH, methyl, phenyl optionally substituted with -OCF3, and tetrahydrofuranyl; L 1 is selected from a direct bond, -O-, -CH2- and -CH=; R 2 Selected from -(C3-C6)cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C6-C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halo, -OH, oxo, -NH2, -NHMe, -NO2, -CN, -SF5, -SiMe3, -B(OH)2, -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3-C6)cycloalkyl, -SO2CH3, -NHC(O)Me, phenyl, benzyl, 1-λ 6 -2-thiazolidine-1,1-dione and pyridinyl, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3-C6)cycloalkyl, phenyl and benzyl is optionally substituted with one or more groups independently selected from halo, -OH, -NH2 and -CF3, And further wherein, when R 2 When it is -(C3-C6)cycloalkyl, R 2 optionally substituted at one ring atom with spirocyclic oxindolyl; L 2 is selected from a direct bond, -CH2-, -CH2CH2-, and -CH2O-, wherein when present, L 2 Optionally substituted with -NH2 or methyl; R 3 is selected from -H, halo, -OH, and methyl optionally substituted with -OH; R 4 is -H or -NH2; R 5 is -H or methyl; X is CH or N; Y is selected from CH, CF and N (provided that when Y is N, X is also N); E is selected from -C(O)-, -S(O)2- and -O- (provided that when E is -O-, X and Y are both CH); and n is 0, 1 or 2.

2. The compound according to claim 1, wherein the compound is a compound of formula (IA) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , L 1 , X, Y and n are as defined in claim 1.

3. A compound according to claim 1 or claim 2, wherein the compound is a compound of formula (IB) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , L 1 and n is as defined in any one of the preceding claims.

4. A compound according to any one of claims 1 to 3, wherein: R 1 is selected from -H, -(C1-C6)alkyl, -(C3-C7)cycloalkyl, -(C4-C8)cycloalkenyl, -(C6-C 10 ) aryl, 4- to 10-membered heterocycloalkyl, 5- to 8-membered heterocycloalkenyl, and 5- to 10-membered heteroaryl, wherein R 1 Optionally one or more R A replace, Each R A independently selected from halo, -OH, -NHR', -CN, oxo, -SO2CH3, -(C1-C3)alkyl, -O(C1-C3)alkyl, -C(O)R", -C(O)NHR', -NHC(O)R", -(C3-C6)cycloalkyl, 3 to 6 membered heterocycloalkyl, phenyl and pyridyl, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl and phenyl is optionally substituted with one or more groups independently selected from halo, -OH, -NH2 and -CN, and / or two of the R A are capable of forming, together with the atom or atoms to which they are attached, a (C3-C6)cycloalkyl or a 3- to 6-membered heterocycloalkyl, wherein each R' is independently selected from -H, methyl and phenyl, and wherein each R" is independently selected from methyl, phenyl optionally substituted with -OCF3, and tetrahydrofuranyl; R 2 Selected from -(C3-C6)cycloalkyl, 5- to 10-membered heterocycloalkyl, -(C6-C 10 ) aryl and 5 to 10 membered heteroaryl, wherein R 2 Optionally one or more R B replace, Each R B Selected from halogen, -OH, -NH2, -NO2, -CN, -SF5, -B(OH)2, -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3-C6)cycloalkyl, -SO2CH3, phenyl, benzyl, 1-λ 6 -2-thiazolidine-1,1-dione and pyridinyl, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl, -(C3-C6)cycloalkyl, phenyl and benzyl is optionally substituted with one or more groups independently selected from halo, -OH, -NH2 and -CF3, And further wherein, when R 2 When it is -(C3-C6)cycloalkyl, R 2 is optionally substituted at one ring atom with spirocyclic oxindolyl; and X and Y are each independently selected from CH and N (provided that when Y is N, X is also N).

5. The compound according to any one of claims 1 to 4, wherein the compound is a compound of formula (IC) or formula (ID) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and L 1 As defined in any one of the preceding claims.

6. A compound according to any one of claims 1 to 5, wherein R 2 Selected from -(C3-C6)cycloalkyl, 5- to 6-membered heterocycloalkyl, 9- to 10-membered heterocycloalkyl, -(C6-C 10 ) aryl, 5- to 6-membered heteroaryl, and 9- to 10-membered heteroaryl, wherein R 2 Optionally one or more R as defined in any of the preceding claims B replace.

7. A compound according to any one of claims 1 to 6, wherein R 2 Selected from: Where R 2 Optionally one or more R as defined in any of the preceding claims B replace.

8. A compound according to any one of claims 1 to 7, wherein R 2 Selected from: Where R 2 Optionally one or more R B Substitute, where each R B Independently selected from halo, -NH2, -O(C1-C3)alkyl, -(C1-C3)alkyl, -(C3-C6)cycloalkyl, -SF5 and -NO2, and wherein each of -O(C1-C3)alkyl, -(C1-C3)alkyl and -(C3-C6)cycloalkyl is optionally substituted by one or more groups independently selected from halo and -CF3.

9. A compound according to any one of claims 1 to 8, wherein at least one R B Yes - SF5.

10. A compound according to any one of claims 1 to 9, wherein R 2 yes:

11. A compound according to any one of claims 1 to 10, wherein R 1 is selected from -H, -(C1-C3)alkyl, -(C3-C6)cycloalkyl, -(C5-C7)cycloalkenyl, -(C6-C 10 ) aryl, 4- to 9-membered heterocycloalkyl, 6-membered heterocycloalkenyl, 5- to 6-membered heteroaryl, and 9- to 10-membered heteroaryl, wherein R 1 Optionally one or more R as defined in any of the preceding claims A replace.

12. A compound according to any one of claims 1 to 11, wherein R 1 Selected from: Where R 1 Optionally one or more R as defined in any of the preceding claims A replace.

13. A compound according to any one of claims 1 to 12, wherein R 1 Selected from: Where R 1 Optionally one or more R A Substitute, where each R A Independently selected from -halo, -OH, -NH2, oxo, -(C1-C3)alkyl, -C(O)R" and -O(C1-C3)alkyl, wherein each (C1-C3)alkyl can be optionally substituted by one or more halo, and wherein each R" is independently selected from methyl, phenyl optionally substituted by -OCF3 and tetrahydrofuranyl.

14. A compound according to any one of claims 1 to 13, wherein R 1 Selected from -(C4-C8)cycloalkenyl, -(C6-C 10 )aryl, 7 to 10-membered polycyclic (e.g., bicyclic) heterocycloalkyl, 5 to 8-membered heterocycloalkenyl, and 7 to 10-membered polycyclic (e.g., bicyclic) heteroaryl, wherein R 1 Optionally one or more R as defined in any of the preceding claims A Substitution, or R 1 It is -(C1-C6)alkyl substituted by one or more substituents selected from -OH, -NH2 and -O(C1-C3)alkyl.

15. A compound according to any one of claims 1 to 14, wherein L 1 It is a direct bond or -CH2-.

16. A compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R 1 , L 1 , R 3 , R 4 and R 5 is as defined in any one of the preceding claims, and wherein: R 2 is selected from -(C3-C6)cycloalkyl (e.g., cyclopropyl), -(C6-C 10 ) aryl, 5- to 10-membered heterocycloalkyl, and 5- to 10-membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B independently selected from halo, -OH, oxo, -NO2, -NH2, -NHMe, -CN, -SF5, -SO2CH3, -NHC(O)Me, -SiMe3, -(C1-C3)alkyl optionally substituted by one or more halo, -O(C1-C3)alkyl optionally substituted by one or more halo, -(C3-C6)cycloalkyl optionally substituted by -CF3, phenyl optionally substituted by one or more halo, -OH or -CF3, benzyl optionally substituted by halo, and 1-λ 6 -2-thiazolidine-1,1-dione, And further wherein, when R 2 When it is cyclopropyl, R 2 is optionally substituted at one ring atom with spirocyclic oxindolyl; and E is -C(O)- or -S(O)2-.

17. A compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein: R 1 is -H, -(C1-C3)alkyl, -(C4-C6)cycloalkyl, -(C5-C7)cycloalkenyl, -(C6-C 10 ) aryl or 4 to 9 membered heterocycloalkyl, 6 membered heterocycloalkenyl, 5 to 6 membered heteroaryl and 9 to 10 membered heteroaryl, wherein R 1 Optionally one or more R A Substitute, where each R A independently selected from halo, -OH, oxo, -NH2, -NHMe, -C(O)OH, -C(O)Me, -SO2CH3, -NHC(O)R", -(C1-C3)alkyl, -O(C1-C3)alkyl, cyclopropyl, oxetanyl, sulfolane, phenyl, benzyl and pyridyl, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl and phenyl is optionally substituted with one or more groups independently selected from halo, -OH and -NH2, wherein each R" is independently selected from methyl and tetrahydrofuranyl; L 1 is a direct bond or -CH2-; and R 2 Selected from -(C3-C6)cycloalkyl, -(C6-C 10 ) aryl, 5- to 6-membered heterocycloalkyl, and 5- to 10-membered heteroaryl, wherein R 2 Optionally one or more R B Substitute, where each R B independently selected from halogen, -NO2, -NH2, -NHMe, -NHAc, -O(C1-C3)alkyl, -SF5, -SiMe3, -(C1-C3)alkyl, 1-λ 6 -2-thiazolidine-1,1-dione, phenyl, benzyl and -(C3-C6)cycloalkyl optionally substituted with -CF3, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl, phenyl and benzyl is optionally substituted with one or more groups independently selected from halo, -NH2 and -CF3, and further wherein, when R 2 When it is cyclopropyl, R 2 Optionally substituted at one ring atom with spirocyclic oxindolyl.

18. A compound of formula (IV) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined in any one of the preceding claims, and wherein: p is 1, 2, 3, 4, or 5; and Each R B independently selected from halogen, -NO2, -NH2, -NHMe, -NHAc, -OCH3, -OCF3, -SF5, SiMe3, (C1-C3) alkyl, -O(C1-C3) alkyl, 1-λ 6 -2-thiazolidine-1,1-dione, phenyl and -(C3-C6)cycloalkyl optionally substituted with -CF3, wherein each of -(C1-C3)alkyl, -O(C1-C3)alkyl and phenyl is optionally substituted with one or more groups independently selected from halo, -NH2 and -CF3.

19. A compound of formula (V) or a pharmaceutically acceptable salt thereof, wherein R 1 and L 1 is as defined in any one of the preceding claims, and wherein: R B1 is -H, or is selected from halo (e.g., -F or -Cl), -OH, -NH2, -NHMe, -NHAc, and -NO2; and R B2 Selected from halo (e.g., -Br), -SF5, -SO2CH3, -SiMe3, -(C1-C3)alkyl optionally substituted by one or more halo, -O(C1-C3)alkyl optionally substituted by one or more halo, 1-trifluoromethylcycloprop-1-yl, and phenyl optionally substituted by one or more groups independently selected from halo or -NH2.

20. The compound according to claim 19, wherein R B2 Yes - SF5.

21. A compound of formula (VIII), (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 , R 5 and n is as defined in any one of the preceding claims.

22. A compound selected from: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, - trans-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -cis-[4-[2-(4-aminocyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -1-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]azetidin-1-yl]ethanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-methyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -5-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one, -[4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(azetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1-methylpyrrolidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(2,2-dimethyltetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(6,6-dimethyltetrahydropyran-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(4-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-[1-(2,2-difluoroethyl)azetidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -(4-chloro-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[2-nitro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydrofuran-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(1,1,2,2,2-pentafluoroethyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)cyclohexyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxaspiro[3.3]hept-6-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -(4-methoxy-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -6-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-3-(trifluoromethyl)-1H-pyridin-2-one, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(2,2,2-trifluoroethyl)phenyl]methanone, -[4-(trifluoromethoxy)phenyl]-[4-[2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -(3-methoxy-1-bicyclo[1.1.1]pentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]methanone, -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]methanone, -[4-[2-(5,5-difluoro-3-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone, -[4-(2-pyrrolidin-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-[2-[(1-methyl-4-piperidinyl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone, -[4-[2-(tetrahydropyran-4-ylmethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, -[4-(2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and -[4-[2-[1-(2,2-difluoroethyl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone, and pharmaceutically acceptable salts thereof.

23. A compound selected from: -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(oxetan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-naphthyl-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -1H-indazol-3-yl-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]methanone; -(1-methyl-5-phenyl-pyrazol-3-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3-amino-2-naphthyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-3,4,5,6-tetrafluoro-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[1-isopropyl-2-(trifluoromethyl)benzimidazol-5-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-4-methylsulfonyl-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[3-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-(3-hydroxyphenyl)cyclopropyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[2-chloro-4-(trifluoromethyl)phenoxy]-1-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]propan-1-one; -(3-phenylcyclopentyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-hydroxy-1-[2-(trifluoromethyl)phenyl]pyrazol-3-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[3-amino-4-phenyl-5-(trifluoromethyl)-2-thienyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(7-hydroxy-1H-indol-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -1-[4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1-piperidinyl]ethanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)cyclohexyl]methanone; -1-[4-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1-piperidinyl]ethanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,4-dioxane-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]benzothiophene-5-carbonitrile; -(5-amino-1-phenyl-pyrazol-4-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[2-oxo-2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]ethyl]-4H-1,4-benzoxazin-3-one; -1-(3,4-difluorophenyl)-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -[4-(3-chloro-4-fluoro-phenyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(7-amino-2-methyl-pyrazolo[1,5-a]pyrimidin-6-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -1-[(2-chlorophenyl)methyl]-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -1-(4-fluorophenyl)-4-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]pyrrolidin-2-one; -[1-[(2-chlorophenyl)methyl]pyrazol-4-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-aminophenyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3,6-dichloroimidazo[1,2-a]pyridin-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(4-amino-1-ethyl-pyrazol-3-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(3-aminoquinoxalin-2-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]spiro[cyclopropane-1,3'-indolin]-2'-one; -[1-(2-chlorophenyl)pyrrolidin-3-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(2-amino-4,5-dichloro-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[1-(4-fluorophenyl)imidazol-4-yl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclohexyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxypropyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3-amino-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)cyclohexyl]methanone; -[3-Fluoro-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[(4-methylpiperazin-1-yl)methyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[2-(5-chloro-2-hydroxy-phenyl)thiazol-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-fluoro-5-hydroxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]phenyl]tetrahydrofuran-2-carboxamide; -[4-[2-[5-(hydroxymethyl)isoxazol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -1-ethyl-3-hydroxy-6-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]quinoxalin-2-one; -[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -(4-bromophenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,4-dioxan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -4-[7-[1-[2-amino-4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclohexanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-(4-trimethylsilylphenyl)methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2,2-difluoro-1,3-benzodioxol-5-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(4-bromo-1H-indol-7-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-(trifluoromethyl)-1H-indol-6-yl]methanone; -[4-(Cyclopropyloxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[5,5-difluoro-3-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -2-tetrahydropyran-4-yl-7-[1-[4-(trifluoromethoxy)phenyl]sulfonyl-4-piperidinyl]-3H-imidazo[4,5-b]pyridine; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[rac-(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-methylmorpholin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[6,6-dimethylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[1-(oxetan-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1-(oxetan-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-3-fluoro-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[rac-(2R,3S)-3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(cis)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)cyclohexyl]-[4-(trifluoromethoxy)-1-piperidinyl]methanone; -(trans)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)cyclohexyl]-[4-(trifluoromethoxy)-1-piperidinyl]methanone; -[4-[2-(4-amino-1-methyl-2-oxabicyclo[ 2.1.1]hexan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(7-oxa-4-azaspiro[2.5]octan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclopent-3-en-1-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(2-amino-4-bromo-phenyl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(4-amino-1-methyl-2-oxabicyclo[ 2.1.1]hex-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[2-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-5-(trifluoromethoxy)phenyl]acetamide; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,6-tetrahydropyridin-5-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-phenylpyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-fluoropyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-amino-3,3,3-trifluoro-propyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[6-(aminomethyl)-3-pyridinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[rac-(3R,4S)-4-(4-pyridinyl)pyrrolidin-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-2-bicyclo[2.2.1]hept-5-enyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-2-thienyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidine-4-carbonitrile; -[4-[2-[2-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-aminotetrahydropyran-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-4-methoxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[Pyrrolidin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,4-tetrahydroisoquinolin-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-amino-5-hydroxy-phenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1H-indol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(azetidin-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone 2,2,2-trifluoroacetate -[4-[2-(3-oxa-9-azabicyclo[3.3.1]non-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-amino-3-pyridinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[piperazin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-aminocyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[3-(methylamino)phenyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(2-azabicyclo[4.1.0]hept-7-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-hydroxy-6-(trifluoromethyl)-3-quinolyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-oxabicyclo[3.1.0]hexan-6-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -N-[4-hydroxy-2-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]phenyl]acetamide; -5,6-dimethyl-3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyridin-2-one; -1-[3,5-dimethyl-4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-1H-pyrrol-2-yl]ethanone; -[4-[2-[1-(1,1-dioxothiol-3-yl)-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1-methylsulfonylazetidin-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-hydroxy-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1,4-oxazepan-2-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(1,1,2,2-tetrafluoroethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(1,1,2,2,2-pentafluoroethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(2,2,3,3-tetrafluoro-1,4-benzodioxin-6-yl)-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[rac-(1S,3S)-3-aminocyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-methylpiperazin-1-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[7-oxa-4-azaspiro[2.5]octan-6-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclopent-3-en-1-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(azepan-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[4-amino-1-methyl-2-oxabicyclo[ 2.1.1]hex-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(3-hydroxyphenyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-[rac-(1R,3S)-3-aminocyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-(3-fluoro-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,2,3,6-tetrahydropyridin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -3-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]bicyclo[1.1.1]pentane-1-carboxylic acid; -3-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)piperidine-1-carbonyl]-6-(trifluoromethyl)-1H-pyridin-2-one; -[4-(difluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,1-dioxothiol-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[1,4-oxazepan-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(trans)-4-[7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclohexanecarboxylic acid; -(cis)-[4-[2-[3-aminotetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-amino-4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1,1-dioxothiol-3-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(4-hydroxy-4-methyl-cyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(4-hydroxy-4-methyl-cyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-(1,2,3,6-tetrahydropyridin-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-[Azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[2-[azepan-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(2-cyclopentyl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone hydrochloride; -[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(trans)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-cyclopropyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-(methylamino)-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[4-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[4-[2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -3-methyl-3-[7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]cyclobutanone; -[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(1-hydroxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[(cis)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[(trans)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-fluoro-4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(cis)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[(trans)-2-methyl-4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)azepan-1-yl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[3-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-1-yl]methanone; -[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]octan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]octan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-fluoro-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(cis)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfuryl)phenyl]-[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(oxepan-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-3-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-[6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-(6-fluoro-2-tetrahydrofuran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[4-(hydroxymethyl)-1-piperidinyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-tetrahydropyran-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[2-oxa-5-azabicyclo[2.2.1]hept-1-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[2-[3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-(6-fluoro-2-thiomorpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[6-methylmorpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydrofuran-3-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[morpholin-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -5-[6-fluoro-7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]piperidin-2-one; -(trans)-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-cyclopentyl-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-[3-methoxycyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[oxepan-4-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-[tetrahydrofuran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-hydroxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(2-cyclopentyl-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(3-methoxy-1-bicyclo[1.1.1]pentyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[2-amino-5-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-(2-tetrahydropyran-4-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]methanone; -[4-[2-(1-cyclopropyl-4-piperidinyl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-(6-fluoro-2-morpholin-2-yl-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[2-hydroxy-4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-[3-(trifluoromethyl)-1-bicyclo[1.1.1]pentyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-[tetrahydropyran-2-yl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(4-hydroxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(trans)-(4-(6-fluoro-2-(4-hydroxy-4-methylcyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperidin-1-yl)(4-(pentafluoro-λ 6 -sulfuryl)phenyl)methanone; -(cis)-[4-[6-fluoro-2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(1-methoxy-1-methyl-ethyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[4-[6-fluoro-2-(3-hydroxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -4-(6-fluoro-2-N-morpholino-3H-imidazo[4,5-b]pyridin-7-yl)-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[4-[6-fluoro-2-[4-hydroxy-4-(trifluoromethyl)cyclohexyl]-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(2-oxabicyclo[2.2.2]oct-4-yl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -[4-[2-(3,4,4a,5,7,7a-hexahydro-2H-furo[3,4-b][1,4]oxazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -(trans)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(pentafluoro-λ 6 -sulfanyl)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -2-[6-fluoro-7-[1-[4-(pentafluoro-λ 6 -sulfanyl)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2,3,4a,5,7,7a-hexahydrofuro[3,4-b][1,4]oxazine-4-carboxylic acid; -[4-[2-(1,1-dioxo-1,4-thiazin-2-yl)-6-fluoro-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(pentafluoro-λ 6 -sulfanyl)phenyl]methanone; -[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]-[4-(trifluoromethoxy)phenyl]methanone; -(2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(3-methoxycyclobutyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(cis)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; -(trans)-[2-amino-4-(trifluoromethoxy)phenyl]-[4-[6-fluoro-2-(4-methoxycyclohexyl)-3H-imidazo[4,5-b]pyridin-7-yl]-1-piperidinyl]methanone; and -7-[6-fluoro-7-[1-[4-(trifluoromethoxy)benzoyl]-4-piperidinyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2-oxa-5-azaspiro[3.5]nonane-5-carboxylic acid, and pharmaceutically acceptable salts thereof.

24. A compound according to any one of the preceding claims, wherein the compound has an IC of 0.05 for ERK5. 50 The value is less than about 2 μM, such as less than about 1 μM, 0.5 μM, 0.2 μM, 100 nM or 50 nM.

25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 24 and at least one pharmaceutically acceptable excipient or carrier.

26. A compound according to any one of claims 1 to 24 or a pharmaceutical composition according to claim 25 for use in therapy.

27. A compound according to any one of claims 1 to 24 or a pharmaceutical composition according to claim 25 for use in the treatment or prevention of cancer.

28. The compound or pharmaceutical composition for use according to claim 27, wherein the cancer is characterized by increased expression of MAPK7 and / or increased activity of ERK5.

29. A compound or pharmaceutical composition for use according to claim 27 or claim 28, wherein the cancer is selected from leukemia, breast cancer, multiple myeloma, colon cancer, renal cell carcinoma, mesothelioma, adenocarcinoma, neuroblastoma and hepatocellular carcinoma.

Images